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Vβ EXPRESSION ANALYSIS IN TYPE 1 DIABETES POPULATION AND THEIR 
UNAFFECTED FIRST DEGREE RELATIVES: A PRELIMINARY ANALYSIS 
 
Mei Han, M.S. 
University of Pittsburgh, 2008 
 
Type 1 diabetes (T1D) is an autoimmune disease and is one of the most common diseases of 
children.   It has a significant impact on public health costing millions of dollars in health care 
every year.  Some studies have found that diabetes-associated T-cell receptor (TCR) bias can be 
detected in the peripheral circulation, and precede the onset of T1D by years.  Therefore 
confirmation of this postulate would identify an acceleration time point that could be targeted by 
intervention strategies. 
         The overall purpose of the study is to investigate Vβ expressions in T1D.  This thesis is a 
preliminary analysis to explore the basic relationships among the various data points and 
provides direction for the investigators.  Results show that Vβ1 and Vβ13.1 expressions for new 
onsets were correlated with the number of days since diagnosis.  Significantly higher values were 
observed within 7 days of diagnosis compared to those measured further away.  In comparison to 
FDRs, new onsets with blood drawn within 7 days of diagnosis showed higher Vβ1 values.  
Male FDRs had higher Vβ1 expression than female FDRs.  The Vβ7 expression among black 
new onsets was significantly higher than for whites.  Black FDRs showed higher Vβ1 expression 
and lower Vβ13.1 expression than white FDRs.  Our data suggests that Vβ expression does not 
correlate with antibody status (GAD, IA2, IAA, and ICA) or the number of positive antibodies.  
Moreover, new onsets and FDRs show no significant differences in Vβ expression among 
individuals with different non-ASP status, DQ2 and DQ8 alleles.  Logistic regression models 
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that included all FDRs and new onsets with Vβ data available within 7 days of diagnosis suggest 
that Vβ1, Vβ13.1, DQ8 and age are associated with the onset of diabetes.  Thus, Vβ expression is 
an independent predictor of T1D. 
         We recommend that when designing studies to assess Vβ expression and analyzing the 
resultant data, it is important to consider the timing of the blood draws and the number of days 
since diagnosis. Our evidence suggests that Vβ expression is higher at onset and then decreases 
over time and needs to be taken into account in the design stage and the analysis. 
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1.0  INTRODUCTION 
1.1 DIABETES OVERVIEW 
Diabetes mellitus type 1 (T1DM) has been known as Insulin Dependent Diabetes Mellitus 
(IDDM).  Because Type 1 diabetes is usually diagnosed in children and young adults, it was 
previously known as a disease of children and was called "childhood" or "juvenile" diabetes.  
T1DM is an autoimmune disease that results in the permanent destruction of insulin producing 
beta cells of the pancreas [1].  Insulin is a hormone that is needed to convert sugar (glucose), 
starches and other food into energy needed for daily life.  Type 1 diabetes is fatal unless treated 
with exogenous insulin via injections to replace the missing hormone.  In addition, frequent 
monitoring of blood glucose levels is essential. 
The precise cause of diabetes and mechanisms triggering the beta-cell-specific attack 
remain unclear, despite the evidence that both genetics and environmental factors such as 
enterovirus (EV) and Coxsackie B (CVB) appear to play roles.  There is currently no cure or no 
preventive measure that can be taken against Type 1 diabetes.  Although some clinical trials aim 
to find interventions for preventing or slowing its development, so far none has proven 
successful.  
According to an estimation of the American Diabetes Association [2], there are 20.8 
million Americans (7 percent of the population) who have diabetes.  Unfortunately, only 14.6 
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million (70%) have been actually diagnosed with diabetes, 6.2 million people, or nearly one-
third, are unaware that they have the disease.  Diagnosed diabetes patients account for 5.8 
percent of the total U.S. population.  About 176,500 people aged 20 years or younger have 
diabetes.  This group represents 0.22% of all people in this age group.  About one in every 400 to 
600 children and adolescents has Type 1 diabetes.  The peak incidence of T1DM is 11 years, but 
new cases frequently occur in adulthood.  Type 1 diabetes onset is more common in Caucasians 
than in African Americans.  
Diabetes is the fifth-deadliest disease in the United States and has a huge impact on 
public health.  It is estimated that the total annual economic cost of diabetes was $174 billion in 
2007.  Medical expenditures attributed to diabetes totaled $116 billion, including $27 billion for 
direct diabetes care, $58 billion for diabetes-related chronic complications, and $31 billion in 
excess general medical costs.  Based on death certificate data, diabetes contributed to 233,619 
deaths in 2005.  The toll of diabetes is actually much higher than officially reported since 
diabetes is generally under-reported on death certificates, particularly in the cases of older 
persons with multiples chronic conditions such as heart disease and hypertension.  It is reported 
that 488 of the deaths associated with diabetes occurred among people age under 18 in 2007[2, 
16]. 
1.2 ROLE OF TCR Vβ GENE EXPRESSIONS IN TYPE I DIABETES 
It is generally believed that certain viral infections, especially those caused by enterovirus (EV) 
such as Coxsackie B (CVB) infections, are associated with damage of pancreas β-cell and with 
the clinical onset of diabetes, particularly amongst very young children [4, 5, 6].  CVB can 
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activate a pool of potentially autoreactive T cells present either in the peripheral circulation [3] 
or already accumulated in the periphery of the islets [7].  The repertoire of T cells activated by 
the virus seems to be restricted with expansion of certain variable portions of the β chain (Vβ) of 
the T cell receptor (TCR) [3].  It appears that this selective T cell activation is temporally 
associated with the occurrence of acute CVB infections in T1DM [3].  In particular, exposure to 
multiple CVB infections possibly characterizes the pre-diabetic period, thus reinforcing the 
hypothesis that viral infections can initiate or accelerate the process of β-cell destruction in 
humans [3].  
The destruction of the insulin-producing beta-cells occurs over a prolonged period of 
time, eventually resulting in the delayed onset of the disease [1].  Detection of serum antibodies 
[8, 9, 10] and T-cell sensitization [11] to a vast array of islet-cell antigens during this period 
implies the presence of autoimmunity even at early stages in the course of the disease.  The 
analysis of the T-cell receptor (TCR) repertoire of the circulating T cells is important because it 
might represent a direct means to ascertain the presence of T cells involved in the pathogenesis 
of Type I diabetes eventually infiltrating the pancreatic islets of Langherans [3]. 
A previous study reported that the majority of the islet infiltrating lymphocytes in the 
pancreas of two children who died at the onset of T1D expressed the TCR Vβ7 gene family [12].  
A pilot study demonstrated that the preferential expression of the TCR Vβ 7 gene family can be 
also found in the peripheral blood of T1D patients at diagnosis [3] (Figure 1). There were no 
TCR biases among HLA-matched control subjects.  Pre-diabetic FDRs showed expansion of the 
Vβ 7 gene family nearly four years prior to the onset of clinical diabetes. Other studies have also 
found evidence that diabetes-associated TCR bias can be detected in the peripheral circulation, 
and precede the onset of T1D by years.  
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It has been suggested that the presence of a TCR Vβ 7 expansion among the circulating T 
cells of T1D patients could be associated with the presence of enteroviral infection and of 
increased aggressiveness of the autoimmune insult.  Confirmation of this postulate would 
identify an acceleration time point that could be targeted by intervention strategies and give 
impetus to strategies to prevent such infection. 
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Figure 1: TCR Vβ repertoire from T1D patients and matched–control 
Used with the permission from Luppi P et al. (2000) Restricted TVR Vβ gene expression and 
 enterovirus infection in Type I diabetes: a pilot study  Diabetologia 43: 1484-1497 
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2.0  STATEMENT OF THE PROBLEM  
Overall Specific Aim: Investigation of TCR Vβ gene expression in Type 1 Diabetes  To 
evaluate TCR Vβ expression, including preferential expression of TCR Vβ1, Vβ5.1, Vβ7, 
Vβ13.1, and Vβ20, in circulating T cells from a group of diagnosed T1DM patients and in a 
longitudinal prospective study of a group of high-risk first degree relatives, using the Children's 
Hospital of Pittsburgh T1D registry. 
Hypothesis I: T-cell Vβ repertoire and viral infection  Enteroviral infection or other 
triggering agents of T1D are associated with evidence of infection which induces a lymphocyte 
immune response characterized by a typical T-cell Vβ bias. 
Hypothesis II: T-Cell precedes β-cell antigen-spreading in progression to T1D and is 
precipitated and accelerated by viral infections  T-cell autoimmunity is precipitated by 
environmental triggers such as viral infections and precedes the appearance of autoantibodies in 
FDRs, which allows more sensitive and earlier detection and staging of pre-diabetes 
autoimmunity. T-cell and B-cell responses to increasing numbers of islet autoantigens (antigen 
spreading) is a marker of progressive pre-diabetes.  These hypotheses will be tested by:  
1) The evaluation of the ontogeny of skewing of T-cell Vβ immune responses by 
measuring frequencies of abnormal T-cell Vβ repertoires.  Temporal relationships of these Vβ 
responses and serologic and genomic evidence of enteroviral infections in a prospectively 
followed cohort of FDR’s with high-risk HLA genes will be examined. 
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2) The development and progression (antigen spreading) of both T-cell and B-cell 
autoimmune responses to islet antigens will be related to both T-cell Vβ skewing and these 
measures of enteroviral infection.  
Aim of thesis project: 
This study is still ongoing and the data has not been completely obtained.  Thus, my 
thesis is a preliminary analysis of the available data and explores the basic relationships among 
the various data points and provides direction for the investigators.  The results obtained will be 
conveyed to the researchers so that decisions and future direction of the study will be predicated 
on quantitative information. 
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3.0  MATERIALS AND METHODS 
3.1 AVAILABLE POPULATIONS 
This project is a part of research study on “The Etiology and Epidemiology of Type 1 Diabetes”, 
which is conducted in the Children’s Hospital of Pittsburgh.  The population consists of 665 
subjects enrolled from January 2004 to May 2008.  
The probands, also known as new onsets, in the study were 212 children age 1 through 18 
diagnosed with the onset of Type 1 diabetes.  Peripheral blood mononuclear cells (PBMC) were 
collected at serial time points, at and after the onset of the disease.  The first blood sample was to 
be drawn within 100 days of diagnosis in order to capture the autoantibody status at onset of the 
disease and was considered the baseline, as this status is believed to change over time, especially 
once exogenous insulin treatment has been started.  Additional blood samples were collected at 
routine six month clinic visits. 
 The first degree relatives (FDRs) in the study were biologic parents or siblings of an 
insulin dependent diabetic child (proband) and recruited in the same time frame.  Ages ranged 
from 2 to 54 years among subjects with no diabetes at the time of enrollment.  Their peripheral 
blood mononuclear cells (PBMC) were collected approximately every 6 months.  A total of 453 
FDRs were available from the original Juvenile Onset Diabetes (JOD) and the current Antigen 
Spreading (AGS) studies.  
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3.2 DATA 
Vβ data was provided by Dr. Patrizia Luppi from the Immunogenic Laboratory in the Division of 
Immunogenetics, Department of Pediatrics, University of Pittsburgh.  Vβ expression was 
available for Vβ 1, Vβ 5.1, Vβ 7, Vβ 13.1, and Vβ 20.  Demographic, antibody and genetic data 
was available from the master database of the etiology and epidemiology of Type 1 Diabetes 
study. 
3.3 ANALYTIC STRATEGY AND STATISTICAL METHODS 
Descriptive statistics were provided for the entire study population and for the subgroups of 
diabetic patients and their unaffected first degree relatives (FDRs).  For categorical variables, 
frequency distributions were calculated and chi-square tests and linear trend tests were conducted 
to evaluate associations.  For continuous variables, we estimated such statistics as mean, standard 
deviation, 95% confidence limits.  Pearson correlations were computed to assess the associations 
among some continuous variables.  To assess differences in continuous variables, we performed 
two-sample t-tests for comparison between two categories, the general linear model (GLM) for 
unbalanced analysis, and Duncan’s multiple range tests for multiple groups.  Plots such as 
histogram plots, box plots, and scatter plots were created to explore patterns in the data.  
Multiple logistic regression models were also built to investigate the association between the 
onset of diabetes and potential independent predictors. 
 Results from multiple blood draws were available for some individuals.  For consistency 
we chose only one blood draw to use in our analyses.  Among new onsets it was their baseline 
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blood draw.  For FDR subjects, it was their first draw.  Therefore, we verified that the blood 
draw date was within 100 days of diagnosis for new onsets.  If this was not the case, the subject 
was excluded.  For FDRs, they had to be unaffected for the purpose of these analyses.  
Therefore, the 7 FDRs with diabetes were excluded.  Furthermore, if an individual had multiple 
blood draws, only the earliest was used. 
Statistical Analysis System (SAS) version 9.0 was used for all descriptive statistics, test 
statistics, and graphic displays. 
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4.0  ANALYSIS AND RESULTS  
4.1 DEMOGRAPHICS 
The entire population included 665 participants, 212 probands or new onsets, 453 first degree 
relatives (FDRs).  Table 1 and Table 2 show the distribution of gender and race for the two 
subpopulations: new onset and FDR.  The total population was made up of 40% males and 60% 
females.  Of the 212 new onsets, 62% were males and 38% were females.  Of the 450 FDRs, 
30% were males and 70% were females (Table 1).  Ninety-one percent out of the new onsets and 
97% out of the FDRs were white (Table 2). 
According to the protocol, the study population should be the diabetic individuals whose 
first blood samples were collected within 100 days of diagnosis and the unaffected first degree 
relatives.  We excluded 128 diabetic patients whose first blood samples were drawn beyond 100 
days of diagnosis and 7 converters in FDRs from the entire population.  Thus 84 patients and 446 
FDRs were retained for the analysis.  Table 3 and Table 4 show the distribution of gender and 
race, respectively.  Table 5 shows race (only white and black) distribution by gender for our 
study population.  For the 84 new onsets, 64% were males and 36% were females.  88% were 
white and 10% were black.  Amongst the 74 white new onsets, 62% were males and 38% were 
females.  Out of the 8 black new onsets, 87.5% were males and 12.5% were females.  Of the 443 
FDRs (excluding 3 missing), 30% were males and 70% were females.  97% were white and 2% 
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were black.  In the 428 white FDRs, 30% were males and 70% were females. As for the 9 black 
FDRs, 22% were males and 78% were females.   
 
Table 1: Gender distribution for the whole population 
Gender New Onsets FDRs 
Count Percent (%) Count Percent (%) 
Male 132 62.3 134 29.8 
Female 80 37.7 316 70.2 
Total 212 100.0 450 100.0 
    
            Note: Frequency missing = 3 
 
 
Table 2: Race distribution for the whole population 
Gender New Onsets FDRs 
Count Percent (%) Count Percent (%) 
White 193 91.0 435 97.3 
Black 15 7.1 9 2.0 
Asian 0 0.0 1 0.2 
Other* 4 1.9 2 0.5 
Total 212 100.0 447 100.0 
    
              Note: Frequency missing = 6 
         * including multiple races 
 
 
Table 3: Gender distribution for the study population 
 
Gender 
New Onsets FDRs 
Count Percent (%) Count Percent (%) 
Male 54   64.3 132   29.8 
Female 30   35.7 311   70.2 
Total 84 100.0 443 100.0 
   
               Note:  Frequency missing = 3 
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Table 4: Race distribution for the study population 
 
Gender 
New Onsets FDRs 
Count Percent (%) Count Percent (%) 
White 74 88.1 428 97.3 
Black 8 9.5 9 2.0 
Asian 0 0.0 1 0.2 
Other* 2 2.4 2 0.5 
Total 84 100.0 440 100.0 
    
              Note: * including multiple races 
            Frequency missing = 6 
 
 
 
 
Table 5: Race distribution by gender for the study population 
 
Race* 
 
Gender 
New Onsets FDRs 
Count Percent (%) Count Percent (%) 
 
White 
    Male 46   62.2 128   29.9 
    Female 28   37.8 300   70.1 
    Total 74 100.0 428 100.0 
 
Black 
    Male 7   87.5 2   22.2 
    Female 1   12.5 7   77.8 
    Total 8 100.0 9 100.0 
 
        Note:   * Only white and black 
 
4.2 VΒ EXPRESSIONS FOR NEW ONSETS AND FDRS 
4.2.1 Correlations between Vβ expressions 
The first blood samples were used in this analysis.  Table 6 shows the correlations between all 
the Vβ expressions.  From the p values we observed that for new onsets, Vβ1 was correlated with 
Vβ5.1, Vβ13.1, and Vβ20; and Vβ13.1 was correlated with Vβ20.  For FDRs, Vβ7 was 
correlated with Vβ5.1, and Vβ13.1; and Vβ13.1 was correlated with Vβ20. 
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Table 6: Correlations between Vβ expressions 
Coefficient 
p-value 
 
Variable  
 
Vβ 1 
 
Vβ 5.1 
 
Vβ 7 
 
Vβ 13.1 
 
Vβ 20 
       
New Onset Vβ 1 1.0000 0.2343 
0.0341 
0.0275 
0.8063 
0.3227 
0.0031 
0.2412 
0.0290 
       
 Vβ 5.1  1.0000 0.0333 
0.7664 
0.0779 
0.4866 
0.1934 
0.0818 
       
 Vβ 7   1.0000 -.0813 
0.4678 
0.0618 
0.5810 
       
 Vβ 13.1    1.0000 0.5395 
<.0001 
       
 Vβ 20     1.0000 
       
FDR Vβ 1 1.0000 0.0509 
0.2933 
-.0813 
0.0931 
-.0587 
0.2266 
0.0829 
0.0876 
       
 Vβ 5.1  1.0000 0.1929 
<.0001 
0.0427 
0.3768 
-.0679 
0.1597 
       
 Vβ 7   1.0000 -.0954 
0.0482 
-.0400 
0.4086 
       
 Vβ 13.1    1.0000 0.1280 
0.0079 
       
 Vβ 20     1.0000 
       
 
4.2.2 Vβ expressions by days since diagnosis for new onsets 
The new onsets in this study were the individuals with their first blood samples drawn within 100 
days of diagnosis.  We assessed if Vβ expressions were correlated with the number of days from 
the date of diagnosis to the time of the first blood draw.  If some correlations existed, the whole 
time period (100 days) was to be divided into two time periods: within 7 days and 8-100 days.  
We would investigate the significance of Vβ expressions in these two different time periods.   
  13
Table 7 shows the correlations between Vβ expressions and the number of days between 
the date of diagnosis and the date of the blood draw.  It appears that Vβ1 and Vβ13.1 were 
significantly correlated with the days, whereas Vβ20 was a borderline and also show somewhat 
correlation with the days.  From Figure 2 decreased tendencies were observed in the Vβ1 
expression and the Vβ13.1 expression, indicating the expression of Vβ1 and Vβ13.1 gene 
families tended to decrease as the time elapsed since diagnosis.  A similar pattern was also noted 
in the Vβ20 gene family, even though the trend was not significant. 
 We further detected the changes in Vβ expression in the two time periods.  Referencing 
to Table 8 and Figure 3, it appears that all the Vβ expressions except the Vβ7 expression were 
higher within 7 days of diagnosis relative to the values between 8 to 100 days of diagnosis.  
Significant changes were observed in both Vβ1 and Vβ13.1 gene families.  For the Vβ1 and 
Vβ13.1 gene families, significantly higher values (p = 0.0004, p < 0.0001) were measured within 
7 days of diagnosis in contrast to the values measured between 8 to 100 days of diagnosis.  As 
for the Vβ20 expression, a borderline, a slightly higher value was noted within 7 days of 
diagnosis compared to the value measured between 8 to 100 days of diagnosis (p = 0.0511).  The 
results demonstrated the time effect on Vβ expression.  
 
Table 7: Correlations between Vβ expressions and days since diagnosis  
 
Coefficient 
 p-value 
 
Vβ 1 
 
Vβ 5.1
 
Vβ 7
 
Vβ 13.1 
 
Vβ 20
      
No. of Days -0.3751 -0.1264 0.0890 -0.4011 -0.1956 
 0.0005 0.2579 0.4268 0.0002 0.0782 
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 Figure 2: Scatter plots for Vβ expressions vs days since diagnosis 
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Figure 3: Vβ expressions by days since diagnosis 
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Table 8: Vβ expressions by days since diagnosis 
Variable No. of Days N Means Std. Dev Min Max p-value 
        
Vβ 1 Within 7 days 22 3.99 0.88 2.51 5.93 0.0004 
 8 - 100 days 60 3.19 0.86 1.52 5.01  
        
Vβ 5.1 Within 7 days 22 5.20 1.45 3.14 8.12 0.2160 
 8 - 100 days 60 4.78 1.32 1.88 10.2  
        
Vβ 7 Within 7 days 22 2.32 0.78 1.06 3.67 0.2198 
 8 - 100 days 60 2.54 0.68 1.06 4.42  
        
Vβ 13.1 Within 7 days 22 2.26 0.83 1.07 4.16 <.0001 
 8 - 100 days 60 1.29 0.81 0.00 3.20  
        
Vβ 20 Within 7 days 22 2.46 1.16 0.12 5.82 0.0511 
 8 - 100 days 60 1.96 0.97 0.16 3.60  
        
    
4.2.3 Vβ expressions by subpopulation 
In this portion, we first assessed whether any differences existed in the expression of Vβ gene 
families between two subpopulations: FDRs and new onsets with their first blood samples drawn 
within 7 days of diagnosis.  Table 9 shows that with the exception of Vβ1 expression every Vβ 
expression in new onsets had no significant differences from the value in FDRs.  Based on the 
two-sample t-tests for Vβ expressions, the results indicate that for the Vβ1 gene family, a 
significantly lower value (p = 0.0017) was observed in FDRs (mean = 3.24%±1.09SD) compared 
to the new onsets whose first blood samples were collected within 7 days of diagnosis (mean = 
3.99%±0.88SD). 
Then we assessed the differences in the expression of Vβ gene families between two 
subpopulations: FDRs and new onsets with their first blood samples drawn within 100 days of 
diagnosis.  Table 10 shows that with the exception of the Vβ13.1 expression every Vβ expression 
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in new onsets had no significant differences from the value in FDRs.  For the Vβ13.1 gene family, 
a lower value was observed in new onsets (mean = 1.55%±0.92SD) relative to the FDRs 
(mean=2.05%±0.85SD), which was significantly different (p < 0.0001). 
 We found that the two comparisons had totally different results.  The results of the 
second comparison show that the Vβ13.1 expression changed in a counter intuitive direction, that 
is, the Vβ13.1 expression was lower in new onsets than in FDRs.  The most possible reason is 
the time effect on Vβ expression.  Based on the analysis in 4.2.2 we knew that all the Vβ 
expressions except the Vβ7 expression in new onsets had negative correlations with the days.  As 
time elapsed since diagnosis, the Vβ expressions decreased so that the Vβ1 expression in new 
onsets was not significantly higher than in FDRs, and the Vβ13.1 expression in new onsets 
decreased dramatically so that it was significantly lower than in FDRs.  Therefore, it is 
recommended for the study that the baseline be restricted to the blood samples within 7 days of 
diagnosis. 
 It was shown that some subjects had multiple blood draws.  For the new onsets whose Vβ 
expressions were available within 7 days of diagnosis, seven with 2 blood draws were identified.  
Table 11 indicates that with the exception of the Vβ7 expression, all the other Vβ expressions 
declined over time compared to the baseline.  However, further analysis can not be conducted 
due to the small sample size (n = 7).  
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Table 9: Vβ expressions for new onsets and FDRs 
Variable Subjects N* Mean Std Dev Min Max p-value 
       
Vβ 1 New Onset 22 3.99 0.88 2.51 5.93 0.0017 
 FDR 428 3.24 1.09 0.84 10.3  
        
Vβ 5.1 New Onset 22 5.20 1.45 3.14 8.12 0.5656 
 FDR 432 5.04 1.22 1.94 10.9  
        
Vβ 7 New Onset 22 2.32 0.78 1.06 3.67 0.4926 
 FDR 432 2.49 1.11 0.76 12.5  
        
Vβ 13.1 New Onset 22 2.26 0.83 1.07 4.16 0.2671 
 FDR 430 2.05 0.85 0.18 9.07  
        
Vβ 20 New Onset 22 2.46 1.16 0.12 5.82 0.1959 
 FDR 430 2.17 1.05 0.02 7.65  
       
    
Note: * Results not available for every Vβ expression 
    
 
 
 
Table 10: Vβ expressions for new onsets and FDRs 
Variable Subjects N* Mean Std Dev Min Max p-value 
       
Vβ 1 New Onset 82 3.41 0.93 1.52 5.93 0.2021 
 FDR 428 3.24 1.09 0.84 10.3  
        
Vβ 5.1 New Onset 82 4.89 1.36 1.88 10.2 0.3032 
 FDR 432 5.04 1.22 1.94 10.9  
        
Vβ 7 New Onset 82 2.48 0.71 1.06 4.42 0.9531 
 FDR 432 2.49 1.11 0.76 12.5  
        
Vβ 13.1 New Onset 82 1.55 0.92 0.00 4.16   <.0001 
 FDR 430 2.05 0.85 0.18 9.07  
        
Vβ 20 New Onset 82 2.10 1.04 0.12 5.82 0.5820 
 FDR 430 2.17 1.05 0.02 7.65  
       
 
Note: * Results not available for every Vβ expression 
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Table 11: Differences in Vβ expressions between two blood draws 
Variable N Mean Std Dev Min Max 
      
Vβ 1 7 -0.9771 1.6029 -3.50 0.69 
Vβ 5.1 7 -0.5771 1.5656 -3.07 1.70 
Vβ 7 7 0.7729 1.3034 -0.80 2.22 
Vβ 13.1 7 -0.2186 0.8921 -1.43 1.27 
Vβ 20 7 -0.6729 0.6538 -1.76 -0.05 
      
 
4.2.4 Vβ expressions by gender 
The expression of Vβ gene families by gender are shown in Table 12.  Based on the results of the 
two-sample t-tests, there were no significant differences in Vβ expressions between males and 
females in new onsets.  With the exception of the Vβ1 expression, for FDRs, all the other Vβ 
expressions in males did not statistically differ from those in females.  However, the Vβ1 
expression in males (mean = 3.45%±1.22SD) was significantly higher (p = 0.0095) than the 
value in females (mean = 3.15%±1.02SD) (Figure 4). 
 
Table 12: Vβ expressions by gender 
Subject Variable Gender N* Mean Std Dev Min Max p-value 
       
New Onset Vβ 1  Male 54 3.52 0.90 1.86 5.93 0.1241 
  Female 28 3.19 0.95 1.52 4.80  
         
 Vβ 5.1  Male 54 5.06 1.41 1.88 10.2 0.1286 
  Female 28 4.57 1.22 2.03 6.26  
         
 Vβ 7  Male 54 2.57 0.68 1.36 4.25 0.1353 
  Female 28 2.32 0.75 1.06 4.42  
         
 Vβ 13.1  Male 54 1.59 0.93 0.06 4.16 0.6055 
  Female 28 1.48 0.91 0.00 3.20  
         
 Vβ 20  Male 54 2.15 1.00 0.16 5.82 0.5117 
  Female 28 1.99 1.11 0.12 3.61  
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Table 12 continued 
 
Subject Variable Gender N* Mean Std Dev Min Max p-value 
       
FDR Vβ 1   Male 129 3.45 1.22 1.02 10.3 0.0095 
  Female 299 3.15 1.02 0.84 6.30  
         
 Vβ 5.1  Male 129 5.07 1.31 1.98 10.9 0.7413 
  Female 303 5.03 1.18 1.94 8.56  
         
 Vβ 7  Male 129 2.57 1.47 0.88 12.5 0.3174 
  Female 303 2.45 0.91 0.76 10.4  
         
 Vβ 13.1  Male 129 2.03 0.75 0.18 4.84 0.7139 
  Female 301 2.06 0.90 0.24 9.07  
         
 Vβ 20  Male 129 2.08 0.98 0.08 7.65 0.2884 
  Female 301 2.20 1.08 0.02 7.22  
       
 
   Note: * Results not available for every Vβ expression 
 
 
 
Figure 4: Vβ 1 expression by gender for FDRs 
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4.2.5 Vβ expressions by race 
Table 4 indicates that most subjects in our study population were white, followed by black, with 
few were Asians and other races.  Therefore we only considered white and black.  Table 13 
shows Vβ expressions by race and the p values which were based on the two-sample t-tests for 
the comparison of the Vβ expressions between white and black in new onsets and FDRs.  It 
appears that the Vβ7 expression for the black new onsets was 3.14%±0.62SD, which was 
significantly higher than the value for the white new onsets (mean = 2.42%±0.69SD) with p 
value of 0.0057.  For the Vβ1 gene family, the black FDRs (mean = 4.07%±1.44SD) showed 
significantly higher value (p= 0.0216) than the white FDRs (mean = 3.22%±1.08SD).  For the 
Vβ13.1 expression, the black FDRs (mean = 1.27%±0.77SD) was significantly lower (p = 
0.0050) than the white FDRs (mean = 2.08%±0.85SD). 
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Table 13: Vβ expressions by race 
Subject Variable Race N* Mean Std Dev Min Max p value 
     
New Onset Vβ 1 White 72 3.36 0.92 1.52 5.87 0.1939 
  Black 8 3.81 1.05 2.61 5.93  
         
 Vβ 5.1 White 72 4.78 1.31 1.88 10.2 0.1197 
  Black 8 5.56 1.64 3.85 8.12  
        
 Vβ 7 White 72 2.42 0.69 1.06 4.42 0.0057 
  Black 8 3.14 0.62 2.54 4.20  
        
 Vβ 13.1 White 72 1.51 0.88 0.00 4.16 0.5560 
  Black 8 1.72 1.29 0.06 4.11  
        
 Vβ 20 White 72 2.02 0.96 0.12 4.03 0.1596 
  Black 8 2.57 1.57 0.36 5.82  
     
FDR Vβ 1 White 413 3.22 1.08 0.85 10.3 0.0216 
  Black 9 4.07 1.44 2.05 7.31  
         
 Vβ 5.1 White 417 5.02 1.22 1.94 10.9 0.1080 
  Black 9 5.68 0.80 4.85 7.45  
        
 Vβ 7 White 417 2.49 1.12 0.76 12.5 0.5144 
  Black 9 2.73 0.88 1.39 4.48  
        
 Vβ 13.1 White 415 2.08 0.85 0.18 9.07 0.0050 
  Black 9 1.27 0.77 0.59 3.05  
        
 Vβ 20 White 415 2.16 1.04 0.02 7.65 0.0742 
  Black 9 2.79 1.18 0.63 4.25  
     
 
      Note: * Results not available for every Vβ expression 
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 Figure 5: Vβ 7 expression by race for new onsets  
 
 
 
Figure 6: Vβ 1 expression by race for FDRs 
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 Figure 7: Vβ 13.1 expression by race for FDRs 
 
4.2.6 Vβ expressions by positive antoantibodies 
The presence of autoantibodies in the pancreatic islet cells is often discovered in diabetic 
patients.  We detected four such antibodies: glutamic acid decarboxylase (GAD), insulinoma-
associated protein 2 (IA-2), insulin autoantibodies (IAA), and islet cell antibodies (ICA).  The 
previous studies have demonstrated that up to 90% of newly diagnosed diabetics have at least 
one of these antibodies in contrast to just 1% of people in the general population [15].  In our 
study we tested each new onset for the antibodies.  Then we investigated if the expression of 
TCR Vβ gene families was associated with the antibodies.  The Vβ expressions by positive 
antibodies GAD, IA-2, IAA, and ICA in new onsets are shown in Table 14 to Table 17, 
respectively.  Table 18 shows Vβ expression by the number of positive antibodies.  The 
comparison of each Vβ expression by positive antibodies was conducted by using the GLM 
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analysis and all the p values were greater than 0.05.  It appears that for new onsets the expression 
of TCR Vβ gene families was not associated with positive autoantibodies GAD, IA-2, IAA, ICA, 
and the number of antibodies. 
 
 
Table 14: Vβ expressions by antibody GAD for new onsets 
Variable N/P N Mean Std Dev Min Max p value 
       
Vβ 1 N 34 3.23 0.93 1.52 5.01 0.0517 
 P 42 3.65 0.89 1.73 5.93  
        
Vβ 5.1 N 34 4.70 1.25 2.03 6.60 0.4614 
 P 42 4.92 1.29 1.88 8.12  
        
Vβ 7 N 34 2.50 0.63 1.33 4.42 0.9528 
 P 42 2.49 0.78 1.06 4.25  
        
Vβ 13.1 N 34 1.66 0.89 0.08 4.16 0.5422 
 P 42 1.53 0.95 0.00 4.11  
        
Vβ 20 N 34 2.29 0.98 0.20 4.03 0.2078 
 P 42 1.98 1.10 0.12 5.82  
       
        Note: N = Negative    P = Positive 
 
 
 
Table 15: Vβ expressions by antibody IA-2 for new onsets 
Variable N/P N Mean Std Dev Min Max p value 
       
Vβ 1 N 30 3.35 0.78 1.85 5.01 0.5891 
 P 47 3.47 1.03 1.52 5.93  
        
Vβ 5.1 N 30 5.00 1.03 3.09 6.60 0.6675 
 P 47 4.85 1.59 1.88 10.2  
        
Vβ 7 N 30 2.43 0.51 1.06 3.37 0.5179 
 P 47 2.54 0.83 1.06 4.42  
        
Vβ 13.1 N 30 1.39 0.88 0.00 3.08 0.2771 
 P 47 1.63 0.98 0.00 4.16  
        
Vβ 20 N 30 2.00 0.89 0.16 3.60 0.7176 
 P 47 2.09 1.12 0.12 5.82  
       
        Note: N = Negative    P = Positive 
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Table 16: Vβ expressions by antibody IAA for new onsets 
Variable N/P N Mean Std Dev Min Max p value 
       
Vβ 1 N 15 3.83 0.81 2.51 5.93 0.8989 
 P 13 3.88 1.08 1.73 5.87  
        
Vβ 5.1 N 15 4.95 1.38 3.14 8.12 0.2768 
 P 13 5.51 1.29 3.48 8.08  
        
Vβ 7 N 15 2.25 0.74 1.06 3.67 0.3491 
      P 13 2.53 0.78 1.40 3.68  
        
Vβ 13.1 N 15 2.09 0.87 0.90 4.16 0.7927 
 P 13 2.00 0.93 0.42 4.11  
        
Vβ 20 N 15 2.37 0.91 0.12 3.61 0.7832 
 P 13 2.48 1.16 1.04 5.82  
       
 
    Note: N = Negative    P = Positive 
 
 
Table 17: Vβ expressions by antibody ICA for new onsets 
Variable N/P N Mean Std Dev Min Max p value 
       
Vβ 1 N 27 3.34 0.85 1.85 5.93 0.4514 
 P 49 3.51 0.98 1.52 5.97  
        
Vβ 5.1 N 27 5.00 1.23 3.09 8.12 0.5759 
 P 49 4.81 1.50 1.88 10.2  
        
Vβ 7 N 27 2.34 0.57 1.06 3.67 0.1354 
      P 49 2.59 0.77 1.33 4.42  
        
Vβ 13.1 N 27 1.46 0.96 0.00 3.08 0.6683 
 P 49 1.55 0.93 0.00 4.16  
        
Vβ 20 N 27 2.13 0.99 0.16 3.61 0.9962 
 P 49 2.13 1.09 0.16 5.82  
       
 
      Note: N = Negative    P = Positive 
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Table 18: Vβ expressions by number of positive antibodies 
 
Variable 
Number of 
positive 
antibodies 
 
N 
 
Mean 
 
Std Dev Min 
 
Max 
 
p value 
      
Vβ 1 0 15 2.93 0.70 1.85 4.30 0.0816 
 1 14 3.65 0.52 2.80 5.01  
 2 22 3.42 1.13 1.52 5.93  
 3 23 3.48 0.78 2.16 4.83  
 4 6 4.07 1.38 1.73 5.87  
        
Vβ 5.1 0 15 4.91 1.21 3.09 6.60 0.5824 
 1 14 4.94 0.90 3.26 6.11  
 2 22 4.92 1.81 2.03 10.2  
 3 23 4.63 1.11 1.88 6.14  
 4 6 5.70 1.85 3.48 8.08  
        
Vβ 7 0 15 2.40 0.39 1.90 3.15 0.3131 
 1 14 2.30 0.62 1.06 3.21  
 2 22 2.40 0.85 1.06 4.42  
 3 23 2.75 0.69 1.39 4.25  
 4 6 2.35 0.99 1.40 3.65  
        
Vβ 13.1 0 15 1.34 0.95 0.08 3.08 0.0862 
 1 14 1.42 0.88 0.00 2.86  
 2 22 1.85 0.81 0.33 4.16  
 3 23 1.29 0.93 0.00 3.20  
 4 6 2.20 1.05 1.14 4.11  
        
Vβ 20 0 15 2.18 1.05 0.20 3.61 0.7748 
 1 14 2.10 1.05 0.16 4.03  
 2 22 2.05 0.92 0.12 3.59  
 3 23 1.97 1.04 0.16 3.30  
 4 6 2.60 1.65 1.04 5.82  
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4.2.7 Vβ expressions and BMI / BMIZ 
Body mass index (BMI) and z-score for BMI-for-age (BMIZ) are important factors contributing 
to Type 1 diabetes.  BMI is calculated by the formula:  BMI = weight (kg) / [height (m)]2 .  Table 
19 shows the correlations between Vβ expressions and BMI at baseline or BMI at 3 months, and 
BMIZ at baseline or BMIZ at 3 months for new onsets.  From the correlation coefficients and the 
corresponding p values we concluded that the expression of TCR Vβ gene families had no 
correlations with BMI at baseline, BMI at 3 months, BMIZ at baseline, and BMIZ at 3 months. 
  
Table 19: Correlations between Vβ expressions and BMI / BMIZ  
Coefficient 
p-value 
 
N 
 
Vβ 1 
 
Vβ 5.1 
 
Vβ 7 
 
Vβ 13.1 
 
Vβ 20 
      
BMI 80 -.0684 -.0129 -.0661 -.0501 -.0841 
  0.5466 0.9098 0.5633 0.6593 0.4582 
       
BMI:3 months 75 0.0151 0.0254 -.0800 0.0155 -.0814 
  0.8977 0.8287 0.4952 0.8951 0.4874 
       
BMIZ 80 -0.1196 -0.0334 -0.1148 -0.0147 0.0284 
  0.2906 0.7688 0.3105 0.8968 0.8028 
       
BMIZ:3 months 75 0.1510 -0.0184 -0.0115 0.1238 0.0757 
  0.1959 0.8753 0.9217 0.2898 0.5188 
      
4.2.8 New onsets vs. FDRs with ASP haplotype 
The FDRs carrying ASP or 0 non-ASP haplotype are individuals with the least risk of diabetes 
among FDRs.  In the 446 FDRs, 40 were the individuals with ASP haplotype.  We compared 
them with the 23 new onsets with their first blood samples collected within 7 days of the 
diagnosis to assess the differences in Vβ expressions between these two groups.   
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Two-sample t-test was performed for each Vβ gene family.  We found that the Vβ1 
expression in the FDRs carrying ASP haplotype (mean = 3.47%±0.92SD) was significant lower 
(p = 0.0348) than that in new onsets (mean = 3.99%±0.88SD), which is similar to the result in 
the comparison between the new onsets and all the FDRs.  As for other Vβ gene families, there 
were no significant differences between new onsets and the FDRs with ASP alleles (Table 20).  
 
Table 20: Two-sample t-test for Vβ expressions (new onsets vs ASP FDRs) 
 Mean     
Variables New Onset         FDR Mehtods DF t-value p-value 
       
Vβ 1 3.99 3.47 Pooled 59 -2.16 0.0348 
Vβ 5.1 5.20 4.90 Pooled 59 -0.90     0.3703 
Vβ 7 2.32 2.50 Pooled 59 0.83 0.4116 
Vβ 13.1 2.26 1.96 Pooled 59 -1.61 0.1117 
Vβ 20 2.46 2.23 Pooled 59 -0.86 0.3942 
       
4.3 VΒ EXPRESSIONS AND HLA GENES 
The fact that the first degree relatives of T1D probands appear to have a higher risk of 
developing diabetes indicates that there might be a genetic susceptibility to diabetes.  The 
Human Leukocyte Antigen (HLA) genes are identified as diabetes susceptibility genes and play 
the largest role in a genetically heterogenous disease, comprising approximately 50% of the 
genetic risk [13, 14].  We assessed whether an expression of certain TCR Vβ gene families 
associates with HLA genes. 
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4.3.1 Vβ expressions by non-ASP haplotype  
Multiple studies demonstrated a strong correlation between having a non-charged amino acid 
such as alanine, valine, or serine at codon 57 (non-ASP) in diabetic patients instead of having 
aspartic acid (ASP) as was most often seen in non-diabetic patients.  Therefore, the HLA results 
were stratified by non-ASP haplotype.  For the non-ASP hyplotype, each of the participants was 
evaluated for the presence of zero (ASP/ASP), one (Non-ASP/ASP), and two non-ASP alleles 
(Non-ASP/ Non-ASP).  For those with one non-ASP plus DQB1*0602 was recorded separately 
as Non-ASP/0602, which shows a protective effect against the development of T1D even in the 
presence of autoantibodies.  The order of risk from lowest to highest is ASP/ASP, non-ASP/0602, 
non-ASP/ASP, and non-ASP/non-ASP.  32 of the FDRs were unable to determine their status 
and need a further analysis of the alleles.  
As seen in Table 21 below, out of the 77 patients, only 1% of the patients were in the 
ASP/ASP group, 99% had at least one non-ASP HLA haplotype, including 3% with non-
ASP/0602 which is a protective haplotype, 25% with one non-ASP allele and 71% with 2 non-
ASP alleles.  The higher incidence in the non-ASP group is to be expected as it is the presence of 
non-ASP alleles that is associated with the risk of developing T1D.  Looking at the presence of 
non-ASP in the 407 FDRs, 90% of them had at least one non-ASP HLA haplotype with a break 
down of 45% with one non-ASP allele, 34% with 2 non-ASP alleles, and 11% with the non-
ASP/0602 allele.  10% of FDRs had 0 non-ASP HLA haplotype.  A Chi-Square test and a 
Cochran-Armitage trend test were performed.  It appears that differences existed among non-
ASP haplotype categories (p < 0.0001), which showed a linear tendency (p = 0.0027).   
Figure 8 shows Vβ expressions by non-ASP haplotype for the study population. 
According to the data in Table 22, lower Vβ7 expressions were measured in T1D patients 
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carrying the ASP/ASP and non-ASP/0602 haplotype with means 1.91% and 1.88% in contrast to 
values of 2.58% and 2.50% in those with the non-ASP/ASP and non-ASP/non-ASP alleles.  The 
lowest Vβ7 expression was observed in the FDRs carrying the non-ASP/0602 haplotype (mean = 
2.05%±0.76SD) in contrast to values ranging from 2.50% to 2.57% in other haplotype groups.  
The results of the Duncan’s multiple range test indicated FDRs carrying the non-ASP/0602 
haplotype had significant lower Vβ7 expression than other FDRs.  This evidence supports the 
fact that DQB1*0602 is a protective haplotype.  For the TCR Vβ13.1 gene family, the lowest 
expression was detected in the ASP/ASP group of new onset with mean 0.25% compared to 
values ranging from 1.50% to 1.93% in the other haplotypes.  The highest Vβ13.1 expression for 
FDRs was found in the Non-ASP/Non-ASP group (mean = 2.18%±1.07SD) relative to values 
ranging from 1.96% to 2.01% in other haplotype groups.  Using the GLM analysis, however, we 
concluded that both new onsets and FDRs showed no significant differences in each Vβ 
expression among the individuals with different non-ASP haplotypes. 
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Table 21: Non-ASP haplotype distribution for new onsets and FDRs 
Frequency    
Percent          
RowPct         
Col Pct 
 
 
ASP/ASP 
Non-ASP
/0602
Non-ASP
/ASP
 
Non-ASP 
/Non-ASP Total
      
New Onset 1 
0.21 
1.30 
2.44 
2
0.41
2.60
4.35
19
3.93
24.68
9.41
55 
11.36 
71.43 
28.21 
77
15.91
   
FDR 40 
8.26 
9.83 
97.56 
44
9.09
10.81
95.65
183
37.81
44.96
90.59
140 
28.93 
34.40 
71.79 
407
84.09
   
Total 41 
8.47 
46
9.50
202
41.74
195 
40.29 
484
100.00
      
 
 
 
 
Table 22: Vβ expressions by non-ASP haplotype 
 
Subject 
 
Variable 
 
ASP Haplotype N* Mean 
Std 
Dev 
 
Min 
 
Max 
      
New Onset Vβ 1 ASP/ASP 1 2.92 . 2.92 2.92 
  Non-ASP/0602 2 3.97 0.47 3.64 4.30 
  Non-ASP/ASP 19 3.20 0.89 1.59 4.80 
  Non-ASP/Non-ASP 53 3.44 0.98 1.52 5.93 
        
 Vβ 5.1 ASP/ASP 1 3.27 . 3.27 3.27 
  Non-ASP/0602 2 6.24 0.50 5.89 6.60 
  Non-ASP/ASP 19 4.10 1.06 2.03 6.26 
  Non-ASP/Non-ASP 53 5.12 1.37 1.88 10.2 
        
 Vβ 7 ASP/ASP 1 1.91 . 1.91 1.91 
  Non-ASP/0602 2 1.88 1.17 1.06 2.71 
  Non-ASP/ASP 19 2.58 0.83 1.33 4.42 
  Non-ASP/Non-ASP 53 2.50 0.68 1.06 4.25 
        
 Vβ 13.1 ASP/ASP 1 0.25 . 0.25 0.25 
  Non-ASP/0602 2 1.93 0.19 1.80 2.07 
  Non-ASP/ASP 19 1.64 0.78 0.00 3.03 
  Non-ASP/Non-ASP 53 1.50 0.94 0.00 4.11 
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Table 22 continued 
 
 
Subject 
 
Variable 
 
ASP Haplotype N* Mean 
Std 
Dev 
 
Min 
 
Max 
 
New Onset Vβ 20 ASP/ASP 1 2.12 . 2.12 2.12 
  Non-ASP/0602 2 1.31 1.68 0.12 2.49 
  Non-ASP/ASP 19 2.00 1.10 0.22 3.61 
  Non-ASP/Non-ASP 53 2.10 1.03 0.16 5.82 
      
FDR Vβ 1 ASP/ASP 39 3.47 0.92 1.70 5.17 
  Non-ASP/0602 43 3.35 1.23 0.90 6.13 
  Non-ASP/ASP 179 3.27 1.14 1.02 10.3 
  Non-ASP/Non-ASP 135 3.14 1.04 0.84 6.95 
        
 Vβ 5.1 ASP/ASP 39 4.90 1.11 2.70 8.04 
  Non-ASP/0602 43 5.20 1.29 2.54 8.14 
  Non-ASP/ASP 180 4.94 1.15 1.94 8.61 
  Non-ASP/Non-ASP 137 5.08 1.27 1.98 10.9 
        
 Vβ 7 ASP/ASP 39 2.50 0.81 1.16 5.45 
  Non-ASP/0602 43 2.05 0.76 1.05 6.23 
  Non-ASP/ASP 180 2.57 1.05 0.76 11.3 
  Non-ASP/Non-ASP 137 2.56 1.39 0.88 12.5 
        
 Vβ 13.1 ASP/ASP 39 1.96 0.61 0.85 3.31 
  Non-ASP/0602 43 2.01 0.64 0.52 3.73 
  Non-ASP/ASP 178 1.97 0.76 0.18 4.84 
  Non-ASP/Non-ASP 137 2.18 1.07 0.26 9.07 
        
 Vβ 20 ASP/ASP 39 2.23 0.95 0.20 4.09 
  Non-ASP/0602 43 2.15 1.08 0.02 5.16 
  Non-ASP/ASP 178 2.07 0.99 0.06 7.22 
  Non-ASP/Non-ASP 137 2.29 1.17 0.04 7.65 
        
 
  Note: * Results not available for every Vβ expression 
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Figure 8: Vβ expressions by non-ASP haplotype 
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4.3.2 Vβ expressions by DQ2/DQ8 allele 
The DQ2 and DQ8 alleles have been shown to trigger an increased genetic risk in developing 
T1D and are indicators for diabetes risk.  The DQ results were stratified by the presence of the 
DQ2 and DQ8 alleles.  Each of the subjects was assessed for the presence of the DQ2 
(DQA1*0501-DQB1*0201) and DQ8 (DQA1*0301-DQB1*0302) alleles.  Recorded results 
indicated if there was one (DQ2/X) or two (DQ2/DQ2) copies of the DQ2 haplotype, one 
(DQ8/X) or two (DQ8/DQ8) copies of the DQ8 haplotype.  The order of risk from highest to 
lowest is DQ2/DQ8 (~1:15), DQ8/DQ8 (~1:60-200), DQ8/X (~1:60-200), DQ2/DQ2 (~1:60-
200), and DQ2/X (~1:300) (where “X” indicates the presence of any other alpha and beta allele 
with the exception of DQB1*0602) [15]. 
4.3.2.1 Vβ expressions by DQ2 allele 
Individuals were classified by the presence of 0 (X/X), 1 (DQ2/X), or 2 (DQ2/ DQ2) copies of 
the DQ2 alleles (where “X” indicates the presence of any other alpha and beta allele with the 
exception of DQB1*0602).  
In regard to the DQ2 alleles, Table 23 shows that 55% of the new onsets and 61% of the 
FDRs possessed no DQ2 alleles, whereas 45% of the new onsets and 39% of the FDRs had at 
least 1 DQ2 allele. 
Based on the GLM analysis, there were no significant differences in each Vβ expression 
for new onsets and FDRs.  Table 24 and Figure 9 show that there were increasing tendencies in 
Vβ5.1, Vβ7, and Vβ20 expressions for new onsets with the increase in the number of DQ2 
alleles.  Similar patterns were also noted in the Vβ1 and Vβ5.1 expressions for FDRs. 
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Table 23: Number of DQ2 alleles distribution for new onsets and FDRs 
Frequency Number of DQ2 alleles  
Percent             
RowPct            
Col Pct             
 
0 
 
1 
 
2 
 
Total 
     
New onset      42 
  8.16 
54.55 
13.50 
     30 
  5.83 
38.96 
15.96 
       5 
  0.97 
  6.49 
31.25 
     77 
14.95 
     
FDR    269 
52.23 
61.42 
86.50 
   158 
30.68 
36.07 
84.04 
     11 
  2.14 
  2.51 
68.75 
   438 
85.05 
     
Total    311 
60.39 
   188 
36.50 
     16 
   3.11 
     515 
100.00 
     
 
Note: Frequency Missing = 15 
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Table 24: Vβ expressions by DQ2 allele 
 
Subject 
 
Variable 
Number of 
DQ2 alleles N* Mean 
Std 
Dev 
 
Min 
 
Max 
      
New Onset Vβ 1 0 40 3.31 0.89 1.59 4.83 
  1 30 3.53 1.06 1.52 5.93 
  2 5 3.19 0.54 2.44 3.89 
        
 Vβ 5.1 0 40 4.59 1.45 1.88 10.2 
  1 30 5.16 1.30 3.41 8.12 
  2 5 5.36 0.62 4.60 6.00 
        
 Vβ 7 0 40 2.46 0.76 1.06 4.42 
  1 30 2.52 0.72 1.36 4.20 
  2 5 2.62 0.63 1.63 3.14 
        
 Vβ 13.1 0 40 1.48 0.92 0.00 3.20 
  1 30 1.67 0.90 0.06 4.11 
  2 5 1.06 0.58 0.12 1.65 
        
 Vβ 20 0 40 1.89 1.14 0.12 4.03 
  1 30 2.25 0.96 0.36 5.82 
  2 5 2.25 0.65 1.28 2.86 
      
FDR Vβ 1 0 261 3.22 1.00 0.84 6.30 
  1 152 3.27 1.22 1.03 10.3 
  2 11 3.73 1.24 1.58 6.10 
        
 Vβ 5.1 0 263 4.86 1.13 1.98 8.14 
  1 154 5.31 1.28 1.94 10.9 
  2 11 5.40 1.36 2.77 7.57 
        
 Vβ 7 0 263 2.42 0.75 0.76 6.23 
  1 154 2.58 1.43 0.88 12.5 
  2 11 2.04 0.52 1.36 2.82 
        
 Vβ 13.1 0 261 2.10 0.81 0.18 7.55 
  1 154 1.99 0.91 0.24 9.07 
  2 11 1.99 1.07 0.68 4.89 
        
 Vβ 20 0 261 2.18 1.07 0.02 7.65 
  1 154 2.19 1.04 0.10 6.94 
  2 11 1.69 0.76 0.04 2.80 
      
 
    Note: * Results not available for every Vβ expression 
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 Figure 9: Vβ expressions by DQ2 allele 
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4.3.2.2 Vβ expressions by DQ8 allele 
Individuals were also classified as having 0 (X/X), 1 (DQ8/X), or 2 (DQ8/ DQ8) copies of the 
DQ8 alleles (where “X” indicates the presence of any other alpha and beta allele with the 
exception of DQB1*0602). 
Table 25 indicates that 62% of the FDRs had no DQ8 alleles and 38% possessed at least 
one DQ8 allele.  In the breakdown, almost 36% were DQ8 heterozygotes and 2% were DQ8 
homozygotes.  Of the 77 new onsets, individuals with 0, 1, and 2 DQ8 haplotypes were 52%, 
43%, and 5%, respectively. 
Referencing to Table 26 and Figure 10, for the Vβ13.1 gene family, both new onsets and 
FDRs carrying zero DQ8 allele showed the lowest value.  As the number of the DQ8 alleles 
increased, the Vβ13.1 expression for both new onsets and FDRs increased.  A similar tendency 
can be observed in the Vβ1 gene family for new onsets.  However, the results based on the GLM 
analysis indicate that there were no significant differences in each Vβ expression by the number 
of DQ8 alleles for both new onsets and FDRs. 
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Table 25:  Number of DQ8 alleles distribution for new onsets and FDRs 
Frequency Number of DQ8 alleles  
Percent            
RowPct            
Col Pct             
 
0 
 
1 
 
2 
 
Total 
     
New onset      40 
  7.77 
51.95 
12.90  
     33 
  6.41 
42.86 
         17.37 
     4 
0.78 
5.19 
           26.67 
     77 
14.95 
     
FDR    270 
52.43 
61.64 
87.10 
   157 
30.49 
35.84 
82.63 
   11 
2.14 
2.51 
       73.33 
   438 
85.05 
     
Total    310 
60.19 
190 
         36.89 
   15 
2.91 
    515 
100.00 
     
 
        Note: Frequency Missing = 15 
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Table 26: Vβ expressions by DQ8 allele 
 
Subject 
 
Variable 
Number of 
DQ8 alleles N* Mean 
Std 
Dev 
 
Min 
 
Max 
     
New Onset Vβ 1 0 39 3.34 0.91 1.52 5.87 
  1 32 3.42 1.04 1.67 5.93 
  2 4 3.67 0.33 3.29 4.09 
        
 Vβ 5.1 0 39 4.76 1.23 2.42 8.08 
  1 32 5.04 1.59 1.88 10.2 
  2 4 4.61 0.96 3.26 5.48 
        
 Vβ 7 0 39 2.58 0.66 1.33 4.20 
  1 32 2.40 0.81 1.06 4.42 
  2 4 2.34 0.64 1.67 2.98 
        
 Vβ 13.1 0 39 1.50 0.95 0.00 4.11 
  1 32 1.54 0.88 0.00 3.09 
  2 4 1.70 0.53 1.18 2.40 
        
 Vβ 20 0 39 2.15 1.05 0.20 5.82 
  1 32 1.89 1.07 0.12 4.03 
  2 4 2.48 0.79 1.45 3.31 
     
FDR Vβ 1 0 262 3.35 1.13 1.02 10.3 
  1 151 3.09 1.03 0.84 6.95 
  2 11 2.92 0.79 1.23 3.80 
        
 Vβ 5.1 0 264 5.15 1.20 1.94 10.9 
  1 153 4.85 1.21 1.98 8.14 
  2 11 4.73 1.16 3.24 6.26 
        
 Vβ 7 0 264 2.48 1.13 1.10 12.5 
  1 153 2.45 0.91 0.76 6.63 
  2 11 2.55 0.65 1.42 3.70 
        
 Vβ 13.1 0 262 1.97 0.71 0.18 4.89 
  1 153 2.17 1.04 0.26 9.07 
  2 11 2.35 0.92 0.82 4.14 
        
 Vβ 20 0 262 2.16 0.98 0.04 5.16 
  1 153 2.19 1.19 0.02 7.65 
  2 11 2.12 0.83 0.22 3.28 
     
 
     Note: * Results not available for every Vβ expression 
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 Figure 10: Vβ expressions by DQ8 allele 
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4.4 AGE EFFECT ON VΒ EXPRESSIONS 
Table 27 shows that the average age for new onsets was 9.4, ranging from 1 to 18, and the 
average age for FDRs was 33.7, ranging from 2 to 54.  In new onsets, all Vβ expressions were 
not correlated with age (Table 28 and Figure 11).  However, the evidence that the Vβ5.1 
expression was correlated with age was observed in FDRs (Table 28 and Figure 12).  
We further investigated the expression of Vβ gene families among 5-year age groups.  
Table 33 and Figure 13 in Appendix A show Vβ expressions by age group for new onsets.  Table 
34 and Figure 14 in Appendix B show Vβ expressions by age group for FDRs.  The GLM 
analyses were conducted to test the significance of the age groups that may contribute to any 
differences in each Vβ gene family.  The results demonstrate that each Vβ gene family appeared 
to be not significantly different among four age groups in new onsets.  But in FDRs the Vβ5.1 
expression in age group 50 to 55 years (mean = 6.83%±0.68SD) was significantly higher than 
other age groups (p = 0.0015). 
 
Table 27:  Mean ages for new onsets and FDRs 
Subjects N Mean Std Dev Min Max 
      
New Onset          84 9.4 4.16 1.0 18.0 
FDR 443 33.7 12.72 2.0 54.0 
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 Figure 11: Scatter plots for Vβ expressions vs age for new onsets 
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Figure 12: Scatter plots for Vβ expressions vs age for FDRs 
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Table 28: Correlations between Vβ expressions and age 
Coefficient 
p-value 
 
Vβ 1 
 
Vβ 5.1 
 
Vβ 7 
 
Vβ 13.1 
 
Vβ 20 
      
New Onset -.0404 0.0222 -.1076 0.0364 -.0702 
 0.7185 0.8428 0.3359 0.7457 0.5307 
      
FDR -.0808 0.1848 -.0329 0.0305 -.0131 
 0.0949 0.0001 0.4959 0.5288 0.7862 
4.5 LOGISTIC REGRESSION 
In the final portion of our analysis, logistic regression modeling was conducted to identify 
independent factors that are associated with Type 1 diabetes.  We included all FDRs and only 
new onsets with a blood draw within seven days of diagnosis.  The factors considered included 
Vβ1, Vβ5.1, Vβ7, Vβ13.1, Vβ20, age at the blood draw, the number of the DQ2 and DQ8 
alleles, race and gender.  HLA haplotype was not included in the models as only one new onset 
was in the ASP/ASP group, the remainder being Non ASP.  Four logistic regression models were 
built for the purpose of assessing the factors associated with T1D.  Model 1 was fitted with all of 
the 10 independent variables and included DQ2 and DQ8 as categorical variables; Model 2 
included all of these variables and built the regression using forward selection.  Model 3 was 
fitted using all 10 explanatory variables treating DQ2 and DQ8 as continuous;  Model 4 included 
all of these variable and  built the regression using forward selection. 
Irrespective of the way DQ2 and DQ8 were treated, categorical or continuous, Vβ7, DQ8, 
and age at blood draw were predictors (Tables 29 and Table 31).  The estimates and odds ratios 
show that the lower Vβ7 expression indicates higher risk of the disease.  In addition, with the 
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increase in the number of DQ8 alleles, the risk of developing T1D increased significantly, 
whereas the risk of developing T1D decreased significantly as the age at blood draw increased. 
When we fitted the models 2 and 4 with forward selection, we found that Vβ1, Vβ13.1, 
DQ8, and age at the blood draw were important factors associated with T1D.  From estimates 
and odds ratios in Table 30 and Table 32, we see that higher expression of Vβ1 and Vβ13.1 gene 
families, as well as the number of DQ8 alleles is associated with increased risk of the disease.  In 
contrast an inverse relationship with age at blood draw was noted with T1D. 
Hosmer and Lemeshow goodness-of-fit tests all show the model fits well (all p values 
>0.9000).  Based on the AIC criteria, the lowest value was observed in model 4 (Table 32) and 
suggests that this model is the “best” of the four models.   
 
Table 29: Parameter estimates, test statistics, and odds ratio for model 1 
 
Parameter 
 
Estimate 
Standard 
Error 
p-value of 
Wald Statistics 
Odds 
Ratio 
 
AIC 
      
Intercept -4.314      2.545 0.090 0.013 97.872 
Vβ 1 0.575 0.316 0.069 1.778  
Vβ 5.1 0.506 0.340 0.137 1.659  
Vβ 7 -1.162 0.584 0.046 0.313  
Vβ 13.1 0.537      0.389 0.168 1.710  
Vβ 20 0.311 0.309 0.315 1.364  
DQ2-1 0.629 0.729 0.388 1.876  
DQ2-2 -12.00 558.1 0.983 0.000  
DQ8-1      1.175      0.743 0.114 3.239  
DQ8-2 2.966 1.260 0.019 19.41  
Race(black) -0.099      1.689 0.953 0.906  
Gender(female) -0.483      0.680 0.478 0.617  
Age at blood draw -0.183 0.047 <0.001 0.833  
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Table 30: Parameter estimates, test statistics, and odds ratio for model 2 
 
Parameter 
 
Estimate 
Standard 
Error 
p-value of 
Wald Statistics 
Odds 
Ratio 
 
AIC 
      
Intercept -5.171 1.550 0.001 0.006 91.719 
Vβ 1 0.760 0.278 0.006 2.139  
Vβ 13.1 0.769 0.358 0.032 2.157  
DQ8-1     1.087 0.642 0.090 2.965  
DQ8-2 2.649 1.074 0.014 14.15  
Age at blood draw -0.171 0.043 <0.001 0.843  
      
 
           
 
                                     
Table 31: Parameter estimates, test statistics, and odds ratio for model 3 
 
Parameter 
 
Estimate 
Standard 
Error 
p-value of 
Wald Statistics 
Odds 
Ratio 
 
AIC 
      
Intercept -4.638 2.555 0.070 0.010 95.605 
Vβ 1 0.564 0.320 0.078 1.758  
Vβ 5.1 0.510 0.337 0.130 1.665  
Vβ 7 -1.080 0.571 0.059 0.340  
Vβ 13.1 0.511 0.375 0.174 1.666  
Vβ 20 0.348 0.303 0.251 1.416  
DQ2 0.229 0.635 0.718 1.258  
DQ8     1.371 0.581 0.018 3.939  
Race(black) 0.203 1.659  0.902 1.225  
Gender(female) -0.457 0.683 0.503 0.633  
Age at blood draw -0.173 0.044 <0.001 0.841  
      
                        
                                 
Table 32: Parameter estimates, test statistics, and odds ratio for model 4 
 
Parameter 
 
Estimate 
Standard 
Error 
p-value of 
Wald Statistics 
Odds 
Ratio 
 
AIC 
      
Intercept -5.194 1.547 0.001 0.006 89.849 
Vβ 1 0.754 0.277 0.007 2.126  
Vβ 13.1 0.751 0.353 0.033 2.120  
DQ8      1.238 0.494 0.012 3.449  
Age at blood draw -0.169 0.042 <0.001 0.845  
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5.0  CONCLUSIONS 
As this is a preliminary analysis of the partially available data, we presented only general 
summaries of the data.  All of our work was exploratory and not hypothesis testing.   
For new onsets, correlations were indentified between the number of days from diagnosis 
and Vβ expression.  Vβ expression in blood samples collected within one week of diagnosis 
tended to be higher than those collected further away.  For Vβ1 and Vβ13.1 this difference was 
significant and for Vβ20 approached significance.  We had multiple blood draws for a few 
individuals and were able to see a general decrease in Vβ expression at later times.  Thus further 
suggesting a time relationship for Vβ expression.  Therefore when characterizing Vβ expression 
at the time of diagnosis, it is important to obtain samples within a few days of onset.  Sample 
collected at later times may not reflect the activity at baseline.  In analyzing Vβ expression, 
adjustment needs to be made for time since diagnosis.    
To investigate the differences in Vβ expressions between new onsets and FDRs, we first 
assessed the differences in the expression of Vβ gene families between FDRs and new onsets 
whose first blood sample was drawn within 7 days of diagnosis.  The results show that for the 
Vβ1 gene family, a significantly lower value was observed among FDRs compared with the new 
onsets whose first blood sample was drawn within 7 days of diagnosis  (p = 0.0017).  When we 
expanded the number of days since diagnosis in new onsets to 100 days a significantly lower 
value was observed in the Vβ13.1 gene family for new onsets compared with FDRs.  These 
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findings are in contrast with one another and the results of the second comparison showing a 
lower Vβ13.1 expression in new onsets is counter intuitive.  The most possible reason is the time 
effect on Vβ expression.  At onset of diabetes Vβ expression is increased.  However, as time 
since diagnosis elapses, Vβ expression decreases so that the Vβ1 expression in new onsets was 
not significantly higher than in FDRs, and the Vβ13.1 expression in new onsets decreased.  
Therefore, it is highly recommended that the study of baseline Vβ expression be restricted to 
using blood samples within 7 days of diagnosis. 
The forgoing summarizes Vβ expression by various subject characteristics.  We did not 
adjust for time since diagnosis as the choice of samples analyzed appear to be random with 
respect to the number of days since diagnosis.  Among FDRs, there is no corresponding metric, 
and thus no adjustment was possible.  For Vβ expressions by gender, the Vβ1 expression in male 
FDRs was significantly higher than that in females (p = 0.0095).  As for Vβ expressions by race, 
the Vβ7 expression in the black new onsets was significantly higher than that in the white new 
onsets (p = 0.0057).  For the Vβ 1 family, black FDRs showed significantly higher value than 
white FDRs (p = 0.0216).  The Vβ 13.1 expression for black FDRs was significantly lower than 
that for white FDRs (p = 0.0005).  Vβ expressions were not associated with the presence of 
positive antibodies GAD, IA-2, IAA, ICA, or the number of positive autoantibodies.  Findings 
from the GLM analysis suggest no association of Vβ expressions with non-ASP status, the DQ2 
alleles, and the DQ8 alleles for either the new onsets or FDRs.  Assessment of age with Vβ gene 
expressions did not reveal any real association. 
The logistic regression analysis was conducted for the purpose of assessing the factors 
associated with T1D.  All FDRs and those new onsets with Vβ results available within 7 days of 
diagnosis were analyzed.  The potential factors considered were Vβ1, Vβ5.1, Vβ7, Vβ13.1, 
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Vβ20, age at the blood draw, the number of the DQ2 or DQ8 alleles, race and gender.  The HLA 
haplotype was not involved in the analyses due to only one new onset in the ASP/ASP group.  
Four logistic regression models were built.  In different models, we treated DQ2 and DQ8 as 
categorical and continuous.  The models showed similar conclusions that the Vβ1 and Vβ13.1 
gene families, DQ8 alleles, and lower age were independently associated with the onset of T1D. 
In summary, there appears to be some evidence that Vβ expression is higher at the 
diagnosis of T1D in new onsets compared to a control group of FDRs.  Furthermore, this 
elevated level of Vβ expression is transient and begins to diminish over time.  These levels may 
eventually be similar to or possibly lower than levels found in FDRs. 
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APPENDIX A 
VB EXPRESSION BY 5-YEAR AGE GROUP FOR NEW ONSETS 
Table 33: Vβ expressions by age group for new onsets 
Variable Age Group N Mean Std  Dev Min Max 
      
Vβ 1 <6 yrs              17 3.42 1.11 1.52 5.93 
 6 - 10 yrs          32 3.55 0.83 1.85 5.01 
 11 - 15 yrs        28 3.14 0.86 1.59 4.63 
 16 - 20 yrs        5 3.95 1.07 3.40 5.87 
       
Vβ5.1 <6 yrs               17 5.01 1.42 2.03 8.12 
 6 - 10 yrs          32 4.77 1.48 1.88 10.2 
 11 - 15 yrs        28 4.80 1.13 2.42 6.60 
 16 - 20 yrs        5 5.77 1.60 3.93 8.08 
       
Vβ 7 <6 yrs               17 2.55 0.83 1.06 4.42 
 6 - 10 yrs          32 2.60 0.74 1.36 4.25 
 11 - 15 yrs        28 2.32 0.51 1.33 3.37 
 16 - 20 yrs        5 2.39 1.01 1.06 3.65 
       
Vβ13.1 <6 yrs               17 1.29 0.76 0.12 2.86 
 6 - 10 yrs          32 1.72 0.87 0.06 4.11 
 11 - 15 yrs        28 1.54 1.01 0.00 4.16 
 16 - 20 yrs        5 1.42 1.24 0.00 2.54 
       
Vβ20 <6 yrs               17 2.01 0.86 0.12 3.13 
 6 - 10 yrs          32 2.23 1.11 0.16 5.82 
 11 - 15 yrs        28 2.11 1.00 0.20 3.61 
 16 - 20 yrs        5 1.50 1.43 0.16 3.60 
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 Figure 13: Vβ expressions by 5-year age group for new onsets 
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APPENDIX B 
VΒ EXPRESSIONS BY 5-YEAR AGE GROUP FOR FDR’S 
Table 34: Vβ expressions by age group for FDRs 
Variable Age Group N Mean Std Dev Min Max 
      
Vβ 1 <6 yrs               12 3.05 1.04 1.61 5.20 
 6 - 10 yrs          30 3.80 1.17 1.81 7.31 
 11 - 15 yrs        31 3.14 1.02 1.13 5.53 
 16 - 20 yrs        19 3.09 0.83 1.32 5.01 
 21 - 25 yrs        3 2.85 0.54 2.25 3.30 
 26 - 30 yrs        20 3.76 1.04 1.66 5.17 
 31 - 35 yrs        48 3.31 1.05 1.23 6.13 
 36 - 40 yrs        112 3.22 1.02 1.18 6.95 
 41 - 45 yrs        109 3.20 1.26 0.84 10.3 
 46 - 50 yrs        41 3.00 0.93 1.02 5.03 
 51 - 55 yrs        4 2.89 0.64 2.26 3.72 
       
Vβ 5.1 <6 yrs               12 5.07 0.78 4.10 6.32 
 6 - 10 yrs          30 4.66 0.99 2.69 6.51 
 11 - 15 yrs        31 4.76 0.92 2.82 7.57 
 16 - 20 yrs        19 4.24 1.00 2.54 6.03 
 21 - 25 yrs        3 4.35 0.98 3.27 5.19 
 26 - 30 yrs        20 5.32 1.23 3.12 8.61 
 31 - 35 yrs        48 4.99 0.95 2.74 7.23 
 36 - 40 yrs        113 5.04 1.29 1.94 10.9 
 41 - 45 yrs        112 5.20 1.30 2.16 8.56 
 46 - 50 yrs        41 5.33 1.32 1.98 8.04 
 51 - 55 yrs        4 6.83 0.68 6.37 7.83 
       
Vβ 7 <6 yrs               12 2.91 1.00 1.87 5.53 
 6 - 10 yrs          30 2.63 0.70 1.32 4.58 
 11 - 15 yrs        31 2.37 0.44 1.46 3.09 
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Table 34 continued 
 
Variable Age Group N Mean Std Dev Min Max 
 
Vβ 7 16 - 20 yrs        19 2.69 0.80 1.11 3.92 
 21 - 25 yrs        3 1.91 0.17 1.79 2.11 
 26 - 30 yrs        20 2.52 0.66 1.56 4.29 
 31 - 35 yrs        48 2.32 0.75 1.16 4.94 
 36 - 40 yrs        113 2.53 1.37 0.88 12.5 
 41 - 45 yrs        112 2.47 1.34 0.76 11.3 
 46 - 50 yrs        41 2.44 0.95 0.96 6.23 
 51 - 55 yrs        4 2.36 0.41 1.88 2.80 
       
Vβ13.1 <6 yrs               12 1.97 0.38 1.23 2.53 
 6 - 10 yrs          30 2.13 0.63 0.62 3.47 
 11 - 15 yrs        31 1.94 0.59 0.46 3.07 
 16 - 20 yrs        19 2.25 0.68 0.90 3.95 
 21 - 25 yrs        3 1.94 0.89 1.04 2.81 
 26 - 30 yrs        20 2.03 0.88 0.27 3.31 
 31 - 35 yrs        47 1.94 0.80 0.24 3.60 
 36 - 40 yrs        113 2.04 0.66 0.26 3.96 
 41 - 45 yrs        111 1.98 1.00 0.66 9.07 
 46 - 50 yrs        41 2.38 1.29 0.18 7.55 
 51 - 55 yrs        4 2.31 0.53 1.94 3.08 
       
Vβ20 <6 yrs               12 2.27 0.94 0.58 4.15 
 6 - 10 yrs          30 2.13 0.86 0.02 3.92 
 11 - 15 yrs        31 2.14 0.94 0.16 4.09 
 16 - 20 yrs        19 2.09 1.46 0.04 6.94 
 21 - 25 yrs        3 1.70 0.88 0.98 2.69 
 26 - 30 yrs        20 2.50 1.10 0.63 4.09 
 31 - 35 yrs        47 2.23 0.96 0.20 4.81 
 36 - 40 yrs        113 2.20 1.09 0.06 7.22 
 41 - 45 yrs        111 2.11 0.96 0.04 4.95 
 46 - 50 yrs        41 2.13 1.33 0.17 7.65 
 51 - 55 yrs        4 1.70 0.10 1.58 1.79 
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Figure 14: Vβ expression by 5-year age group for FDRs 
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APPENDIX C 
SAS PROGRAM USED FOR THE ANALYSIS 
libname   library  "F:\thesis" ; 
filename  format   "F:\thesis\jod_formats_08_05_01.sas" ; 
filename  format_m   "F:\thesis\jod_formats_mei.sas" ; 
 
run ; 
 
*  Use and create SAS format from existing program; 
 
%include format ; 
%include format_m ; 
run ; 
 
 
title1     "VB Study" ; 
 
 
*  Create permanent SAS data set ; 
 
data library.vb_info  (drop = i) ; 
 
     set library.vb_info_abi_08_07_23 ; 
      
*    Assigning missing values to the data ;  
     missing  m d n r s b ; 
 
     array mpvar_n(*)   _NUMERIC_  ;  t
     do i=1 to dim(tmpvar_n) ; 
        if tmpvar_n(i)=-999 then tmpvar_n(i)="m" ; 
        if tmpvar_n(i)=-888 then tmpvar_n(i)="s" ; 
        if tmpvar_n(i)=-777 then tmpvar_n(i)="b" ; 
     end ; 
 
     array tmpvar_c(*)   _character_ ; 
     do i=1 to dim(tmpvar_c) ; 
        if compress(tmpvar_c(i))="-999" then tmpvar_c(i)="m" ; 
        if compress(tmpvar_c(i))="-888" then tmpvar_c(i)="d" ; 
     end ; 
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      attrib  pid  label = "Participant ID" ; 
 
      *  Extracted date part from variable ;      
      blooddrawdate = datepart(blooddrawdate) ; 
      attrib  blooddrawdate  format = date9.  label = "Blood draw date" ; 
      attrib  countofpid  label = "Number of samples" ; 
      attrib  fid  label = "Family ID" ; 
      attrib  ags  format = lags.  label = "AGS study" ; 
      attrib  agsdisp  format = lagsdisp.  label = "AGS study" ; 
      attrib  gender  format = lgender.  label = "Gender" ; 
      attrib  race  format = lrace.  label = "Race" ; 
 
      *  Extracted date part from variable ;      
      dob = datepart(dob) ; 
      attrib  dob  format = date9.  label = "Birthdate" ; 
 
      *  Extracted date part from variable ;      
      ddx = datepart(ddx) ; 
      attrib  ddx  format = date9.  label = "Date of diagnosis" ; 
 
      attrib  age_dx  label = "Age at diagnosis" ; 
      attrib  age_blooddraw  label = "Age at blood draw" ; 
      attrib  nonasp_status  format = lasp.  label = "ASP status" ; 
      attrib  calc_nonasp  format = lcalc_nonasp.  label = "ASP 
            haplotype" ;  
      attrib  calc_dq2  label = "Number of DQ2 alleles" ; 
      attrib  calc_dq8  label = "Number of DQ8 alleles" ;  
      attrib  vb_1      label = "VB 1 percent expression" ; 
      attrib  vb_5_1    label = "VB 5.1 percent expression" ; 
      attrib  vb_7      label = "VB 7 percent expression" ; 
      attrib  vb_13_1   label = "VB 13.1 percent expression" ; 
      attrib  vb_20     label = "VB 20 percent expression" ; 
 
run ; 
 
 
 
/* Create data set only for the first blood draw*/ 
 
proc sort  data =  library.vb_info ; 
    by pid blooddrawdate; 
run ; 
 
data library.vb_subjec_newonset library.vb_subjec_fdr ; 
      set library.vb_info ; 
      by pid blooddrawdate; 
      pid_first = first.pid; 
      pid_last = last.pid; 
      if first.pid; 
 
      n_day = blooddrawdate - ddx; 
      age = floor((blooddrawdate - dob)/365.25); 
 
      if  0  <= age <6   then agegp_5 = 1; 
      if  6 <= age <11 then agegp_5 = 2; 
      if 11 <= age <16 then agegp_5 = 3; 
      if 16 <= age <21 then agegp_5 = 4; 
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      if 21 <= age <26 then agegp_5 = 5; 
      if 26 <= age <31 then agegp_5 = 6; 
      if 31 <= age <36 then agegp_5 = 7; 
      if 36 <= age <41 then agegp_5 = 8; 
      if 41 <= age <46 then agegp_5 = 9; 
      if 46 <= age <51 then agegp_5 = 10; 
      if 51 <= age <56 then agegp_5 = 11; 
      if 56 <= age <61 then agegp_5 = 12; 
 
      if ags in(1 2 5) then output library.vb_subjec_newonset; 
      else output library.vb_subjec_fdr; 
run ; 
 
/* Create data set only for the probands with the first blood draw within 100 
days of diagnosis */ 
 
data library.vb_subjec_newonset; 
     set brary.vb_s ec_newonset;li ubj  
     if -7 < n_day <=100 and age  < 20 ; 
run; 
 
/* Create data set only for the probands with the first blood draw within 7 
days of diagnosis */ 
 
data library.vb_subjec_newonset_7; 
     set brary.vb_su ec_newonsetli bj ; 
     if -7 < n_day <= 7 and age  < 20 ; 
run; 
 
/*create data set with unaffected FDRs*/ 
 
data library.vb_subjec_fdr; 
     set library.vb_subjec_fdr; 
     if  n_day = . ; 
run; 
 
/* Create data set for the probands with the first blood draw within 100 days 
of diagnosis and unaffected FDRs*/ 
 
data library.vb_subject; 
     merge library.vb_subjec_newonset library.vb_subjec_fdr; 
     by pid; 
     if ags in(1 2 5) then newonset = 1; 
     else if ags in(3 4)then newonset = 0; 
run; 
 
/* Create data set for the probands with the first blood draw within 7 days 
of diagnosis and unaffected FDRs*/ 
 
data library.vb_subject_7; 
     merge library.vb_subjec_newonset_7 library.vb_subjec_fdr; 
     by pid; 
     if ags in(1 2 5) then newonset = 1; 
     else if ags in(3 4)then newonset = 0; 
run; 
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/*create the data set containing variable, n_samples.*/ 
 
proc freq data = library.vb_info ; 
     tables pid / out = vb_freq (drop=percent rename=(count=n_samples)); 
run; 
 
data library.vb_freq; 
     set vb_freq; 
     label n_samples = 'Number of samples'; 
run; 
 
title3    "Participant Summary" ; 
 
proc freq data = library.vb_freq; 
     tables n_samples; 
run; 
 
 
/* Basic information for subjects and samples*/ 
proc freq  data =  library.vb_subject ; 
     tables  gender  race  ags ; 
     tables  n_day nonasp_status  calc_nonasp  calc_dq2  calc_dq8 ; 
run ; 
 
proc freq  data =  library.vb_subject ; 
     tables  ags * (gender  race ) ; 
     format  ags lags_grouped. ; 
run; 
 
proc freq  data =  library.vb_subject ; 
     tables  ags ; 
     format  ags lags_grouped. ; 
run ; 
 
proc freq  data =  library.vb_subject ; 
     tables  ags  * (nonasp_status  calc_nonasp  calc_dq2 calc_dq8)  
           /chisq trend ; 
     format  ags lags_grouped. ; 
run ; 
 
proc freq  data =  library.vb_subject ; 
     where calc_nonasp in(0 1 2 3); 
     tables  ags  *  calc_nonasp /fisher trend expected; 
     format  ags lags_grouped. ; 
run ; 
 
proc means data = library.vb_subject  n mean std median p5 p25 p75 p95 min 
     max range   fw = 4 maxdec = 2 ; 
     var  age_dx ; 
run; 
 
proc means data = library.vb_subject  n mean std median p5 p25 p75 p95 min 
      max range   fw = 4 maxdec = 2 ; 
      class ags;  
      var  n_day age; 
      format ags lags_grouped.; 
run; 
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title3    "Sample summary" ; 
proc means data = library.vb_info  n mean std median p5 p25 p75 p95 min max 
     range   fw = 4 maxdec = 2 ; 
     var  age_blooddraw  vb_1 -- vb_20 ; 
run ; 
 
 
/* *************************************************************************/ 
/*                              New Onset vs FDR                           */            
/***************************************************************************/ 
 
/*Analysis A*/ 
 
/* New Onset VS FDR: mean VB expression based on the 1st blood sample*/ 
 
/* 1. calculate mean VB expression for New Onset and FDR*/ 
 
proc means data = library.vb_subject n mean std median min max range 
     nonobs fw = 4 maxdec = 2 ; 
     class ags; 
     types () ags; 
     format ags lags_grouped.; 
     var vb_1 -- vb_20; 
     title 'Means of VB Expression by AGS Study'; 
run; 
 
/*2. calculate mean VB expression by days since diagnosis for New Onset */ 
 
proc means data = library.vb_subjec_newonset n mean std min max nonobs fw = 4 
maxdec = 2 ; 
     class n_day; 
     format n_day ldaygp.; 
     var vb_1 -- vb_20; 
     title 'Means of VB Expression by days since diagnosis'; 
run; 
 
/*a. Scatter plot For new onsets*/ 
 
proc gplot data rary.vb_subject;  = lib
  where ags in(1 2 5); 
  plot (vb_1 vb_5_1 vb_7 vb_13_1 vb_20) * n_day; 
  title 'New Onsets: Scatter Plot For VB vs. Days'; 
run; 
 
quit; 
 
/*b. t-test for VB expression in new onsets*/ 
 
proc ttest data = library.vb_subject; 
     where ags in(1 2 5) ; 
     class n_day; 
     var vb_1 vb_13_1 vb_20; 
     format n_day ldaygp.; 
run; 
 
 
/*C. correlation between VB's and the days */ 
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proc corr  data = library.vb_subjec_newonset ; 
     var  vb_1 -- vb_20 ;  
     with n_day ; 
run ; 
 
/* 3. Graphs for VB expression: New onset vs FDR*/ 
 
proc sort data = library.vb_subject out = vb_subject; 
     by ags; 
run; 
 
data vb_subject2; 
     set vb_subject; 
     if ags in(1 2 5) then ags_group = "New onset"; 
     else if ags in(3 4) then ags_group = "FDR"; 
     else ags_group = "Unknown"; 
     label ags_group = " Subject";   
run; 
 
 
/*For VB1*/ 
 
title 'New Onset vs FDR for VB1 Expression'; 
 
proc boxplot data = vb_subject2; 
     plot vb_1 * ags_group;  
run; 
 
proc gchart data = library.vb_subject; 
     vbar ags  / sumvar = vb_1 discrete 
           type = mean inside = mean  
      errorbar = top 
           width = 18 space = 4; 
     format ags lags_grouped.; 
run; 
 
*comparison the difference in VB1 between two groups; 
 
proc ttest data = library.vb_subject_7; 
     class newonset; 
     var vb_1 -–vb_20; 
run; 
 
/*4. correlation between VB's */ 
 
proc corr data = library.vb_subject; 
     where ags in(1 2 5); 
     var vb_1 -- vb_20; 
     title 'New Onset: Correlation between VB families '; 
run; 
 
proc corr data = library.vb_subject; 
     where ags in(3 4); 
     var vb_1 -- vb_20; 
     title 'FDRs: Correlation between VB families '; 
run; 
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/*5.Correlation between age and VB's*/ 
 
proc corr data = library.vb_subject; 
     where ags in(1 2 5); 
     var vb_1 -- vb_20; 
     with age; 
     title 'New Onset: Correlation between age and VB families '; 
run; 
 
proc corr data = library.vb_subject; 
     where ags in(3 4); 
     var vb_1 -- vb_20; 
     with age; 
     title 'FDRs: Correlation between age and VB families '; 
run; 
 
/*6.Correlation between BMI and VB's*/ 
 
proc corr data = library.vb_subject; 
     where ags in(1 2 5); 
     var vb_1 -- vb_20; 
     with bmi; 
     title 'New Onset: Correlation between BMI and VB families '; 
run; 
 
/*7.Correlation between BMI_3months and VB's*/ 
 
proc corr data = library.vb_subject; 
     where ags in(1 2 5); 
     var vb_1 -- vb_20; 
     with bmi_3months; 
     title 'New Onset: Correlation between BMI_3months and VB families '; 
run; 
 
/*8.Correlation between BMIZ and VB's*/ 
 
proc corr data = library.vb_subject; 
     where ags in(1 2 5); 
     var vb_1 -- vb_20; 
     with bmiz; 
     title 'New Onset: Correlation between BMIZ and VB families '; 
run; 
 
/*9.Correlation between BMIZ_3months and VB's*/ 
proc corr data = library.vb_subject; 
     where ags in(1 2 5); 
     var vb_1 -- vb_20; 
     with bmiz_3months; 
     title 'New Onset: Correlation between BMIZ_3months and VB families '; 
run; 
 
/*10.VB expression by gender*/ 
 
proc means data = library.vb_subject nonobs n mean std min max range ; 
     class ags gender; 
     var vb_1 --vb_20; 
     title "VB Expression by gender"; 
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     format ags lags_grouped.; 
run; 
 
 
/*11.VB expression by race*/ 
 
proc means data = library.vb_subject nonobs n mean std min max range ; 
     where race in(1 2); 
     class ags race; 
     var vb_1 --vb_20; 
     title "VB Expression by race"; 
     format ags lags_grouped.; 
run; 
 
/*12.VB expression by Positive Antibody: GAD*/ 
 
proc means data = library.vb_subject nonobs n mean std min max range ; 
     where ags in(1 2 5); 
     class pos_antibodies_gad; 
     var vb_1 --vb_20; 
     title "New onset: VB Expression by Positive Antibody: GAD"; 
run; 
  
/*13.VB expression by Positive Antibody: IA2*/ 
 
proc means data = library.vb_subject nonobs n mean std min max range ; 
     where ags in(1 2 5) ; 
     class pos_antibodies_ia2; 
     var vb_1 --vb_20; 
     title "New onset: VB Expression by Positive Antibody: IA2"; 
run; 
  
/*14.VB expression by Positive Antibody: IAA*/ 
 
proc means data = library.vb_subject nonobs n mean std min max range ; 
     where ags in(1 2 5) ; 
     class pos_antibodies_iaa; 
     var vb_1 --vb_20; 
     title "New onset: VB Expression by Positive Antibody: IAA"; 
run; 
  
/*15.VB expression by Positive Antibody: ICA*/ 
 
proc means data = library.vb_subject nonobs n mean std min max range ; 
     where ags in(1 2 5) ; 
     class pos_antibodies_ica; 
     var vb_1 --vb_20; 
     title "New onset: VB Expression by Positive Antibody: ICA"; 
run; 
  
/*16.VB expression by any Positive Antibody*/ 
 
proc means data = library.vb_subject nonobs n mean std min max range ; 
     where ags in(1 2 5) ; 
     class pos_antibodies; 
     var vb_1 --vb_20; 
     title "New onset: VB Expression by Any Positive Antibody: ICA"; 
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run; 
 
/*17.Comparison*/ 
 
/*a.VB by race*/ 
 
title 'VB expression by race'; 
 
/*fo  new r onset*/ 
proc ttest data = library.vb_subject; 
     where race in(1 2) and ags in(1 2 5) ; 
     class race; 
     var vb_1 —- vb_20; 
run; 
 
/*for FDR*/ 
proc ttest data = library.vb_subject; 
     where race in(1 2)and ags in(3 4); 
     class race; 
     var vb_1 -– vb_20; 
run; 
 
 
/*b.VB by gender*/ 
 
title 'VB expression by gender'; 
 
/*for FDR*/ 
proc ttest data = library.vb_subject; 
     where ags in(3 4); 
     class gender; 
     var vb_1 -–vb_20; 
run; 
 
/*c.VB expression by antibody GAD*/ 
 
title 'VB expression by antibody GAD'; 
 
/*fo  New r Onset*/ 
proc ttest data = library.vb_subject; 
     where ags in(1 2 5); 
     class pos_antibodies_gad; 
     var vb_1 -– vb_20; 
run; 
 
/*d.VB expression by antibody IA2*/ 
 
title 'VB expression by antibody IA2'; 
 
/*for New Onset*/ 
proc ttest data = library.vb_subject; 
     where ags in(1 2 5); 
     class pos_antibodies_ia2; 
     var vb_1 –- vb_20; 
run; 
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/*e.VB expression by antibody IAA*/ 
 
title 'VB expression by antibody IAA'; 
 
/*fo  New r Onset*/ 
proc ttest data = library.vb_subject; 
     where ags in(1 2 5); 
     class pos_antibodies_iaa; 
     var vb_1 -– vb_20; 
run; 
 
 
/*f.VB expression by antibody ICA*/ 
title 'VB expression by antibody ICA'; 
 
/*for New Onset*/ 
proc ttest data = library.vb_subject; 
     where ags in(1 2 5); 
     class pos_antibodies_ica; 
     var vb_1 -– vb_20; 
run; 
 
/*g.VB expression by the number of posotive antibodies*/ 
 
title 'VB expression by Number of posotive antibodies'; 
 
/*for New Onset*/ 
 
proc glm data = library.vb_subject; 
      where ags in(1 2 5); 
 class pos_antibodies; 
 model vb_20 = pos_antibodies; 
 means pos_antibodies; 
run; 
 
 
 
/*Analysis B*/ 
 
/* HLA and VB expressions (using the first sample)*/ 
 
* 1. VB ex pression by ASP status; 
proc means data = library.vb_subject n mean std median min max fw = 4 maxdec 
      = 2; 
     class ags nonasp_status; 
     var vb_1 -- vb_20; 
     format ags lags_grouped.; 
     title 'Mean VB Expression by ASP Status'; 
run; 
 
 
* 2. VB expressions by non-ASP Haplotype; 
proc means data = library.vb_subject n mean std median min max fw = 4 maxdec 
       = 2; 
     where calc_nonasp in(0 1 2 3); 
     class ags calc_nonasp; 
     var vb_1 -- vb_20; 
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     format ags lags_grouped.; 
     title 'Mean VB Expressions by non-ASP Haplotype'; 
run; 
 
proc gchart data = library.vb_subject; 
     where calc_nonasp in(0 1 2 3); 
     vbar calc_nonasp / sumvar = vb_1 discrete 
           type = mean mean nozero 
           group = ags gspace = 8 width = 4; 
     format ags lags_grouped.; 
     title 'Mean VB 1 Expression by ASP Haplotype'; 
run; 
 
proc gchart data = library.vb_subject; 
     where calc_nonasp in(0 1 2 3); 
     vbar calc_nonasp / sumvar = vb_5_1 discrete 
             type = mean mean nozero 
        group = ags gspace = 8 width = 4; 
     format ags lags_grouped.; 
     title 'Mean VB 5.1 Expression by ASP Haplotype'; 
run; 
 
proc gchart data = library.vb_subject; 
     where calc_nonasp in(0 1 2 3); 
     vbar calc_nonasp / sumvar = vb_7 discrete 
             type = mean mean nozero 
        group = ags gspace = 8 width = 4; 
     format ags lags_grouped.; 
     title 'Mean VB7 Expression by ASP Haplotype'; 
run; 
 
proc gchart data = library.vb_subject; 
     where calc_nonasp in(0 1 2 3); 
     vbar calc_nonasp / sumvar = vb_13_1 discrete 
             type = mean mean nozero 
        group = ags gspace = 8 width = 4; 
     format ags lags_grouped.; 
     title 'Mean VB 13.1 Expression by ASP Haplotype'; 
run; 
 
proc gchart data = library.vb_subject; 
     where calc_nonasp in(0 1 2 3); 
     vbar calc_nonasp / sumvar = vb_20 discrete 
            type = mean mean nozero 
       group = ags gspace = 8 width = 4; 
     format ags lags_grouped.; 
     title 'Means of VB 20 Expression by ASP Haplotype'; 
run; 
 
 
* 3. VB Ex pressions by Number of DQ2 Alleles; 
proc means data = library.vb_subject n mean std median min max fw = 4  
      maxdec = 2; 
     class ags calc_dq2; 
     var vb_1 -- vb_20; 
     format ags lags_grouped.; 
     title 'Mean VB Expressions by Number of DQ2 Alleles'; 
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run; 
 
proc gchart data = library.vb_subject; 
     vbar calc_dq2 / sumvar = vb_1 discrete 
           type = mean mean nozero 
      group = ags gspace = 8 width = 4; 
     format ags lags_grouped.; 
     title 'Mean VB 1 Expression by Number of DQ2 Alleles '; 
run; 
 
proc gchart data = library.vb_subject; 
     vbar calc_dq2 / sumvar = vb_5_1 discrete 
                  type = mean mean nozero 
                  group = ags gspace = 8 width = 4; 
     format ags lags_grouped.; 
     title 'Mean VB 5.1 Expression by Number of DQ2 Alleles'; 
run; 
 
proc gchart data = library.vb_subject; 
     vbar calc_dq2 / sumvar = vb_7 discrete 
            type = mean mean nozero 
       group = ags gspace = 8 width = 4; 
     format ags lags_grouped.; 
     title 'Mean VB 7 Expression by Number of DQ2 Alleles '; 
run; 
 
proc gchart data = library.vb_subject; 
     vbar calc_dq2 / sumvar = vb_13_1 discrete 
                  type = mean mean nozero 
             group = ags gspace = 8 width = 4; 
     format ags lags_grouped.; 
     title 'Mean VB 13.1 Expression by Number of DQ2 Alleles '; 
run; 
 
proc gchart data = library.vb_subject; 
     vbar calc_dq2 / sumvar = vb_20 discrete 
           type = mean mean nozero 
      group = ags gspace = 8 width = 4; 
      format ags lags_grouped.; 
      title 'Mean VB 20 Expression by Number of DQ2 Alleles '; 
run; 
 
* 4. VB Expressions by Number of DQ8 Alleles; 
proc means data = library.vb_subject n mean std median min max fw = 4  
      maxdec = 2 ; 
     class ags calc_dq8; 
     var vb_1 -- vb_20; 
     format ags lags_grouped.; 
     title 'Mean VB Expression by Number of DQ8 Alleles'; 
run; 
 
proc gchart data = library.vb_subject; 
     vbar calc_dq8 / sumvar = vb_1 discrete 
           type = mean mean nozero 
      group = ags gspace = 8 width = 4; 
     format ags lags_grouped.; 
     title 'Mean VB 1 Expression by Number of DQ8 Alleles '; 
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run; 
 
proc gchart data = library.vb_subject; 
     vbar calc_dq8 / sumvar = vb_5_1 discrete 
           type = mean mean nozero 
      group = ags gspace = 8 width = 4; 
     format ags lags_grouped.; 
     title 'Mean VB 5.1 Expression by Number of DQ8 Alleles '; 
run; 
 
proc gchart data = library.vb_subject; 
     vbar calc_dq8 / sumvar = vb_7 discrete 
           type = mean mean nozero 
      group = ags gspace = 8 width = 4; 
     format ags lags_grouped.; 
     title 'Mean VB 7 Expression by Number of DQ8 Alleles '; 
run; 
 
proc gchart data = library.vb_subject; 
     vbar calc_dq8 / sumvar = vb_13_1 discrete 
           type = mean mean nozero 
      group = ags gspace = 8 width = 4; 
     format ags lags_grouped.; 
     title 'Mean VB 13.1 Expression by Number of DQ8 Alleles '; 
run; 
 
proc gchart data = library.vb_subject; 
     vbar calc_dq8 / sumvar = vb_20 discrete 
                  type = mean mean nozero 
                  group = ags gspace = 8 width = 4; 
     format ags lags_grouped.; 
     title 'Mean VB20 Expression by Number of DQ8 Alleles'; 
run; 
 
 
/*Comparison*/ 
 
/*1.VB expression by non-asp alleles*/ 
 
title 'VB expression by non-asp alleles'; 
 
/*fo  Ner w Onset*/ 
proc glm data = library.vb_subject; 
     where ags in(1 2 5) and calc_nonasp in(0 1 2 3); 
     class calc_nonasp; 
     model vb_5_1 = calc_nonasp; 
     means calc_nonasp /duncan;  
run; 
 
/*for FDR*/ 
proc glm data = library.vb_subject; 
     where ags in(3 4) and calc_nonasp in(0 1 2 3); 
     class calc_nonasp; 
     model vb_20 = calc_nonasp; 
     means calc_nonasp /duncan;  
run; 
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/*2.VB expression by number of DQ2 alleles*/ 
 
title 'VB expression by number of DQ2 alleles'; 
 
/*fo  Ner w Onset*/ 
proc glm data = library.vb_subject; 
     where ags in(1 2 5); 
     class calc_dq2; 
     model vb_7 = calc_dq2; 
     means calc_dq2 /duncan;  
run; 
 
/*for FDR*/ 
proc glm data = library.vb_subject; 
     where ags in(3 4) ; 
     class calc_dq2; 
     model vb_13_1 = calc_dq2; 
     means calc_dq2 /duncan;  
run; 
 
 
/*3.VB expression by number of DQ8 alleles*/ 
 
title 'VB expression by number of DQ8 alleles'; 
 
/*fo  Ner w Onset*/ 
proc glm data = library.vb_subject; 
     where ags in(1 2 5); 
     class calc_dq8; 
     model vb_20 = calc_dq8; 
     means calc_dq8 /duncan;  
run; 
 
/*for FDR*/ 
proc glm data = library.vb_subject; 
     where ags in(3 4) ; 
     class calc_dq8; 
     model vb_20 = calc_dq8; 
     means calc_dq8 /duncan;  
run; 
 
 
 
/*Analysis C*/ 
 
/* Compare VB between new onset and FDRs with only ASP haplotype*/ 
 
/*step 1. create the data set with new onset and FDRs with ASP haplotype */ 
 
data library.vb_newonset_fdrasp; 
     set library.vb_subject; 
     if nonasp_status NE 0 and newonset = 0 then delete; 
run; 
 
proc freq data = library.vb_newonset_fdrasp;; 
     tables  newonset; 
     format newonset lnewonset_group.; 
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run ; 
 
/*step 2. Compare VB between new onset and FDRs with ASP Alleles*/ 
 
/* T o-samw ple t-test */ 
proc ttest data = library.vb_newonset_fdrasp; 
     class newonset; 
     title "Two-sample t-test for VB1"; 
     var vb_1 -– vb_20; 
run; 
 
 
 
/*Analysis E */  
 
/* VB expressions by Age for the subjects */ 
 
/*1. Correlations between VB families and age*/ 
 
proc corr data = library.vb_subject; 
     where ags in (1 2 5); 
     var vb_1 -- vb_20; 
     with age; 
     title ' Correlation for New Onsets between VB family and age'; 
run; 
 
proc corr data = library.vb_subject; 
     where ags in (3 4); 
     var vb_1 -- vb_20; 
     with age; 
     title ' Correlation for FDRs between VB family and age'; 
run; 
 
/* 2. VB expressions by age groups for new onsets*/ 
 
/* a  by 5.  years age group*/ 
proc means data = library.vb_subjec_newonset nonobs n mean std  min max fw = 
      4 maxdec = 2 ; 
     class age; 
     format age lage5yr_t1d.; 
     var vb_1 --vb_20; 
     title 'Mean VB by Age for New Onset'; 
run; 
 
 
/*b. Comparison: VB expression by 5-year age groups */ 
 
title 'New Onset: VB expression by 5-year age groups '; 
 
proc glm data = library.vb_subjec_newonset; 
     class agegp_5; 
     model vb_7 = agegp_5; 
     means agegp_5 /tukey; 
run; 
 
/*c. Scatter plot For new onsets*/ 
proc gplot data = library.vb_subject; 
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  where ags in(1 2 5); 
  plot (vb_1 vb_5_1 vb_7 vb_13_1 vb_20) * age; 
  title 'New Onsets: Scatter Plot For VB vs. Age'; 
run; 
 
/* 3. VB expressions by 5-year age group for FDRs*/ 
 
/*a. VB expressions by 5 years age group */ 
 
proc means data = library.vb_subjec_fdr nonobs n mean std min max fw = 4  
     maxdec = 2 ; 
     class age; 
     format age lage5yr_fdr.; 
     var vb_1 -– vb_20; 
     title 'Mean VB by Age for FDR'; 
run; 
 
/*b. Comparison: VB expression by 5-year age groups */ 
 
title 'FDR: VB expression by 5-year age groups '; 
 
proc glm data = library.vb_subjec_fdr; 
class agegp_5; 
model vb_5_1 = agegp_5; 
means agegp_5 /duncan; 
run; 
 
 
/*c. Scatter plot For FDRs*/ 
proc gplot data ibrary.vb_subject;  = l
  where ags in(3 4); 
  plot (vb_1 vb_5_1 vb_7 vb_13_1 vb_20) * age; 
  title 'FDRs: Scatter Plot For VB vs. Age'; 
run; 
 
 
 
/*Analysis E */  
 
/*Logistic regression */ 
 
title 'Logistic regression'; 
 
/*model 1*/ 
 
proc logistic data = vb_subject  descending ; 
    where race in(1 2) and n_day <= 7 ; 
    class black(ref='0') female(ref='0') calc_dq2(ref='0') calc_dq8(ref='0') 
           / param=ref  ; 
    model newonset = vb_1 vb_5_1 vb_7 vb_13_1 vb_20 
                     calc_dq2 calc_dq8  black female age_blooddraw /expb 
                     selection = none lackfit risklimits  stb ; 
run; 
 
/*model 2*/ 
 
proc logistic data = vb_subject  descending ; 
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    where race in(1 2) and n_day <= 7 ; 
    class  black(ref='0') female(ref='0') calc_dq2(ref='0') calc_dq8(ref='0') 
           / param=ref  ; 
    model newonset = vb_1 vb_5_1 vb_7 vb_13_1 vb_20 
                     calc_dq2 calc_dq8  black female  age_blooddraw /expb 
                     selection = forward lackfit risklimits  stb ; 
run; 
 
/*model 3*/ 
 
proc logistic data = vb_subject  descending ; 
    where race in(1 2) and n_day <= 7 ; 
    class  black (ref='0') female (ref='0') / param=ref  ; 
    model newonset = vb_1 vb_5_1 vb_7 vb_13_1 vb_20 
                     calc_dq2 calc_dq8  black female  age_blooddraw /expb 
                     selection = none lackfit risklimits  stb ; 
run; 
 
/*model 4*/ 
 
proc logistic data b_subject  descending ;  = v
    where race in(1 2) and n_day <= 7 ; 
    class  black (ref='0') female (ref='0') / param=ref  ; 
    model newonset = vb_1 vb_5_1 vb_7 vb_13_1 vb_20 
                     calc_dq2 calc_dq8  black female  age_blooddraw /expb 
                     selection = forward lackfit risklimits  stb ; 
run; 
 
 
/*Analysis F*/ 
 
/*calculate the difference in VB expression between baseline and 1st test and 
the No. of days between baseline and 1st blood draw*/ 
 
/*Step 1: create the data set containing the subjects with more than two 
blood draws*/ 
 
data vb_info_moretests; 
     set library.vb_info ; 
     by pid blooddrawdate; 
     pid_first = first.pid; 
     pid_last = last.pid; 
     n_day = blooddrawdate - ddx; 
     if pid_first = 1 and pid_last = 1 then delete; 
run; 
 
proc sort data = vb_info_moretests; 
     by pid; 
run; 
 
proc rank data = vb_info_moretests out = blooddraw; 
     by pid; 
     var blooddrawdate; 
     ranks blooddraw_no; 
run; 
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/*Step 2: get the data set containing new onsets with their first blood 
samples within 7 days of diagnosis*/ 
 
data  vb_1st ; 
set blooddraw ( keep = pid fid blooddrawdate ags vb_1 --vb_20  
blooddraw_no n_day); 
if blooddraw_no = 1 and -7 < n_day <=7 and ags in(1 2 5); 
rename blooddrawdate = blooddraw_1st 
         vb_1   = vb_1_1st 
         vb_5_1 = vb_5_1_1st 
         vb_7   = vb_7_1st 
    vb_13_1= vb_13_1_1st 
         vb_20  = vb_20_1st; 
run; 
 
/*Step 3: get the data set containing the second blood samples for new 
onsets*/ 
 
data  vb_2nd ; 
set blooddraw ( keep = pid fid blooddrawdate ags vb_1 --vb_20  
          blooddraw_no ); 
      if blooddraw_no = 2 and ags in(1 2 5); 
rename blooddrawdate = blooddraw_2nd 
         vb_1   = vb_1_2nd 
         vb_5_1 = vb_5_1_2nd 
         vb_7   = vb_7_2nd 
    vb_13_1= vb_13_1_2nd 
         vb_20  = vb_20_2nd; 
run; 
 
 
/*Step 4: calculate the difference in VB expression between 1st and 2nd 
sample and the No. of days between 1st and 2nd blood draw*/ 
 
data vb_diff; 
     merge vb_1st (drop = blooddraw_no) vb_2nd (drop = blooddraw_no); 
      by pid; 
days = blooddraw_2nd - blooddraw_1st; 
vb_1_diff   = vb_1_2nd - vb_1_1st; 
vb_5_1_diff = vb_5_1_2nd - vb_5_1_1st; 
vb_7_diff   = vb_7_2nd - vb_7_1st; 
vb_13_1_diff= vb_13_1_2nd - vb_13_1_1st; 
vb_20_diff  = vb_20_2nd - vb_20_1st; 
 
if vb_1_diff = . and vb_5_1_diff = . and vb_7_diff = .  
   and vb_13_1_diff = . and vb_20_diff = . then delete; 
 
label days          = '# of days between baseline and 2nd test' 
      vb_1_diff     = 'VB1 diff. between baseline and 2nd test' 
      vb_5_1_diff   = 'VB5.1 diff. between baseline and 2nd test' 
      vb_7_diff     = 'VB7 diff. between baseline and 2nd test' 
      vb_13_1_diff  = 'VB13.1 diff. between baseline and 2nd test' 
      vb_20_diff    = 'VB20 diff. between baseline and 2nd test' 
      blooddraw_1st = '1st Blood Draw Date' 
      blooddraw_2nd = '2nd Blood Draw Date'; 
 
run; 
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proc print data = vb_diff; 
var pid n_day days vb_1_diff--vb_20_diff; 
run; 
 
/*1. Scatter plot for VB expression vs days*/ 
 
proc gplot data = vb_diff; 
     where ags in(1 2 5); 
     plot (vb_1_diff vb_5_1_diff vb_7_diff vb_13_1_diff vb_20_diff)* days;        
     title 'New Onsets: Scatter Plot For VB_diff vs. Days'; 
run; 
 
quit; 
 
/*3. correlations between Diff. in VB families and days*/ 
 
proc corr data = vb_diff; 
     where ags in(1 2 5); 
     var vb_1_diff -- vb_20_diff; 
     with days; 
     title 'New Onsets: Correlation between VB families and Days'; 
run; 
 
/* 4. Mean VB Expressions Difference between Two Tests */ 
 
proc means data = vb_diff nonobs n mean std median min max clm fw = 4 
     maxdec = 2; 
     var vb_1_diff -- vb_20_diff; 
     title 'Mean VB Expression Difference between Two Tests'; 
run; 
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